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Abstract 
Background: Individuals diagnosed with Autism Spectrum Disorder (ASD) experience lifelong 
challenges which can impact peer relationships, adaptive functioning, and independent living. 
Verbal intelligence has proven to be the strongest indicator of outcomes and responsiveness to 
behavioral intervention, but this property only stabilizes in children between 6 and 8 years of 
age. Behavioral treatment is the primary intervention for individuals diagnosed with ASD, but it 
is most effective when delivered as an early intervention strategy for toddlers and very young 
children. A biomarker which could distinguish treatment resistant subgroups of ASD from would 
allow for the development and implementation of alternative treatments in an attempt to improve 
long term outcomes. 
Methods: Our study used data from 49 participants made available through the National 
Database for Autism Research (NDAR). The sample group contained children between 4 and 11 
years of age diagnosed with ASD and typically developing peers. Our study used EEG and 
behavioral measures to explore whether sample entropy analysis of EEG, as developed by Bosl 
et al. (2011), could distinguish between individuals with ASD and low verbal IQ from their 
average verbal and typically developing peers. 
Results: The analysis we performed found that higher levels of sample entropy were correlated 
with lower ASD symptoms and better adaptive functioning. ANOVA analysis also suggested 
that sample entropy could distinguish ASD and typically developing children. Sample entropy 
was not correlated with verbal IQ and could not distinguish the ASD low verbal IQ group from 
both ASD with average verbal IQ and typically developing groups.  
Conclusion: Researchers interested in identifying biomarkers for treatment resistant ASD should 
look beyond sample entropy for reliable measures. Sample entropy does appear to play a role in 
autistic symptomatology, and greater research into its role as a possible indicator of underlying 
neurological abnormalities should be explored. Researchers may also find value in including 
sample entropy in longitudinal studies to see how this measure changes with behavioral 
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Introduction  
The Most Pressing Need 
  Individuals diagnosed with Autism Spectrum Disorder (ASD) experience a range of 
challenges later in life as a result of their neurodevelopmental condition. These challenges range 
from limited peer interaction, high rates of joblessness, and difficulties managing the demands of 
independent living. Estimates of individuals with ASD facing significant challenges in these 
domains can be as high as 58% (Howlin, Goode, Hutton, & Rutter, 2004). The fundamental 
problem facing clinicians and researchers working with ASD is how to improve outcomes for 
this group. 
 While investigation into the biology of ASD are ongoing, there is no well-defined 
etiology and no reliable pharmacological interventions that target the core symptoms of ASD. 
Behavioral interventions emphasizing early detection and treatment of ASD have proved 
effective, however, outcomes remain poor for many who do not respond as well to these 
interventions as their peers (Eikeseth, 2009). The problem with this situation is that children who 
do not response positively to behavioral intervention have wasted an important developmental 
window wherein treatment is deemed most effective. This has led researchers to investigate early 
markers that might indicate how a child might respond to behavioral intervention. 
 The most reliable predictor of outcomes in ASD is verbal intelligence. The influence of 
this factor has been demonstrated in numerous studies (Anderson, Liang, & Lord, 2014; Lord, 
Bishop, & Anderson, 2015; Kim, Bal, & Lord, 2018), and verbal ability has also been shown to 
be an important factor correlated with responsiveness to behavioral intervention (Fossum, 
Williams, Garon, Bryson, & Smith, 2018).Instruments such as the Mullen Scales of Early 
Learning are used to measure intelligence in very young children with ASD, however, behavioral 
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measures of intelligence at this age are unreliable, with correlation between IQ at age one and 
fifteen being as low as r=.15 (Gottfried, Gottfried, & Guerin, 2009). Intelligence is generally 
believed to stabilize between the ages of 6 and 8, casting doubt upon the reliability of IQ 
measures for children as method of detecting responsiveness to intervention, or predicting later 
outcomes.  
Biological measures that can be reliably implemented, can predict responsiveness to 
intervention, and are correlated with outcomes later in life would be an invaluable contribution to 
this field. These measures could allow for the early detection of treatment resistant ASD, 
allowing for novel interventions to be administered during the crucial developmental window 
associated with better outcomes. Our study investigates whether an early biomarker of ASD may 




 In 2012 ASD in the United States had a prevalence rate among 8-year-old children of 1 in 
68. Prevalence among boys is higher, with 1 in 42 boys receiving the diagnosis compared to 1 in 
189 in girls (Christensen, Baio, & Braun, 2016; Center for Disease Control, 2014). ASD is 
defined behaviorally in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5) and can presently only be diagnosed through behavioral observation. The disorder is 
categorized by deficits in social communication and the presence of restrictive and repetitive 
behaviors. Social communication and social interaction deficits can affect the performance of 
nonverbal communication, reciprocal engagement, and the development of interpersonal 
relationships. Restrictive and repetitive behaviors can include stereotyped motor movements, 
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inflexible adherence to routines, restricted interests, and sensitivity to sensory stimuli (American 
Psychiatric Association, 2013). 
 Although ASD is diagnosed through behavioral observation, it is assumed to be rooted in 
the biology of individuals with the condition. Advances in research investigating the etiology of 
ASD have led to the proposal that ASD be conceptualized as a neurodevelopmental disorder, 
highlighting its biological foundations (Insel, 2014). The systems implicated in ASD are varied, 
ranging from from immunology (Masi et al, 2015) to gastrointestinal problems (Vissoker, Latzer 
& Gal, 2015). The most common and heavily researched domains, however, are genetics and 
neuroscience (Insel, 2014). Research into the genetic underpinnings of ASD has discovered 
several genetic abnormalities responsible for clusters of individuals with the condition, and 
neuroscience research has discovered possible neural systems and processes which may be 
responsible for the symptoms of ASD. 
 Genetics. 
The genomic underpinning of ASD is evidenced by the strong correlation of ASD 
between siblings, specifically between monozygotic twins (Tick et al.,2016). Despite positive 
indications for the genetic causes of ASD, specific genomic disturbances can only account for 
approximately 5% of cases. Three specific genetic disorders present with the behavioral 
symptoms typical of ASD, namely, Rett Syndrome, 22q11.2 Deletion Syndrome (22q11DS) and 
Klinefelter Syndrome. All three of these disorders are excluded from the ASD category precisely 
because they are understood as discrete genetic conditions (Miyake et al., 2011; Manning et al., 
2004; Biswas & Furniss, 2016; van Rijn, 2015).  
These genetic conditions present with behavioral profiles consistent with ASD and shed 
light on the problem of heterogeneity in the field. ASD is a broad phenotype that has made 
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classification using behavioral diagnostic rubrics difficult (Tsai & Ghaziuddin 2013; Young & 
Rodi 2013). Genetic research into the etiology of ASD aims to deal with this heterogeneity by 
identifying discrete genetic conditions responsible for distinct symptom clusters. Research has 
shown that isolation of 22q11DS and Klinefelter Syndrome within a broader group of individuals 
diagnosed with ASD significantly decreases phenotypic heterogeneity of the sample (Bruining et 
al., 2010).  This raises the hope that ASD may be understood as a collection of rare genetic 
disorders, each responsible for a cluster of symptoms within the autism spectrum.   
 Unfortunately, specific genetic explanations for ASD remain elusive aside from the cases 
discussed above. The ability of genetics to explain phenotypic heterogeneity appears to have its 
limits. Chaste et al. (2014) collected a sample of individuals with ASD to explore the 
relationship between genetics and phenotypic heterogeneity. The researchers in this study 
divided the sample into clusters based upon behavior profiles to create homogenous subgroups. 
Then, they compared the genetic makeup between groups to see if genetic heterogeneity had 
likewise been reduced, but it had not. While the possibility of distinct subgroups within ASD 
remain, with strict adherents of this position using the term “autisms” (Cantio, et al., 2016), 
genetics alone cannot currently define this heterogeneous condition. 
 While the genetic disorders discussed above identify gene abnormalities as the ultimate, 
or distal, cause of ASD symptomatology, they implicate neural functioning as the proximate 
cause of ASD behavior profiles. Rett Syndrome, for example, results from a mutation in the 
MeCP2 gene which in turn influences the expression of genes essential for brain development 
(Miyake et al., 2011).  22q11DS also results in structural and connective abnormalities in the 
brain, as well as abnormalities in neurotransmitters such as COMT (Biswas & Furniss 2016). 
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The impact these genetic disorders have on neural development suggest that the brain may be an 
additional candidate system for research into the etiology of ASD. 
Neuroscience. 
The majority of ASD cases are idiopathic, where no clear genetic or environmental cause 
for the disorder has been identified. In these cases, the role of neural systems is paramount, 
because it provides insight into the mechanisms which underpin aberrant behavior, regardless of 
the ultimate underlying cause. Research in the neuroscience of ASD can be generally divided by 
the technology used to investigate the neural system. The most common neuroimaging 
techniques are computed tomography (CT), magnetic resonance imaging (MRI), functional 
magnetic resonance imaging (fMRI), and electroencephalography (EEG). Abnormalities in both 
structure and function of neural systems are investigated by these technologies, with CT and 
MRI used to detect structural abnormalities, and fMRI and EEG used to detect abnormalities in 
functioning. 
Research has discovered abnormalities in several brain regions and networks that are 
implicated in ASD. CT scans have contributed to our understanding of neurobiological 
underpinnings of ASD (Eigsti & Schuh, 2008), and MRI research has been used to inform 
changes in diagnostic criteria of ASD (Pina-Camacho et al., 2013). Structural abnormalities have 
been detected in nearly every region of the brain for individuals with ASD, and these varied 
results are presumed to be the byproduct of the heterogeneity of the condition itself (Sivapalan & 
Aitchison, 2014). Differences are usually determined by greater volume in white or grey matter, 
and a larger volume of neural matter is general found in individuals with ASD.  The wide range 
of brain regions implicated in ASD has led researchers to look beyond the structure of the brain 
and turn their focus to the networks which connect these regions (Sivapalan & Aitchison, 2014). 
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Connectivity between brain regions is often established using fMRI measurements, and 
this has become a leading method for investigating neural system in ASD. Due to its spatial 
resolution of 2-3 millimeters and the ability to monitor neural processing by detecting changes in 
blood flow associated with neural activation, it is a well-suited method for examining neural 
connectivity. fMRI studies have discovered abnormal functioning in the ventral visual cortex, 
prefrontal cortex, anterior cingulate in individuals with ASD (Ewbank et al., 2015; Solomon et 
al., 2015). An emerging field of inquiry has also implicated the cerebellum and its functional 
connectivity to other neural structures (Crippa et al., 2016). While fMRI explores connectivity 
between brain regions by measuring blood flow, EEG can measure connectivity at a finer 
timescale and record the most salient phenomenon in neural networks, namely, the action 
potential and resulting electrical activity. 
An early indication that ASD may involve abnormalities in the brain’s electrical patterns 
was suggested by the high comorbidity between ASD and Epilepsy (Kanner, 2000). These two 
conditions are diagnostically distinct, but researchers have explored the clinical significance of 
individuals presenting with both conditions, finding that the presence of Epilepsy in conjunction 
with ASD is associated with more severe symptomatology and poorer treatment outcomes 
(Viscidi et al., 2013; Schubarata et al., 2015; El Achkar and Spence, 2015). Additional research 
has shown that epileptiform patterns of electrical activity are present in ASD, even in the absence 
of Epilepsy (Spence & Schneider, 2009; Boutros et al. 2015). Bosl, Loddenkemper & Nelson 
(forthcoming) found that specific methods of nonlinear analysis can be used to distinguish ASD, 
Epilepsy, and healthy controls, but that the ASD population represented a midpoint between 
Epilepsy and control groups, suggesting that ASD and Epilepsy may share a common pathology, 
with ASD being a moderate form of the later. In addition to the similarities between ASD and 
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epilepsy, more traditional EEG measurements have found abnormalities in a variety of areas 
including gamma oscillations, theta and beta power spectra and interhemispheric connectivity 
(Maxwell et al., 2015; Bink et al., 2015; Machado et al., 2015; Lazarev et al., 2015;).  
Developmental Trajectories. 
Research into the genetics and neuroscience of ASD continues investigating the 
mechanisms of action and discrete causes of this disorder, but the condition is still diagnosed 
behaviorally. Behavioral conceptions of ASD have evolved over the past few years, in part 
reflecting the discoveries from genetics and neuroscience regarding the etiology of the disorder. 
From a behavioral perspective, the continuity of ASD as a singular disorder has been challenged 
in the research literature (Georgiades et al. 2013; Tek, Mesite, Fein, & Naigles 2013; Sullivan, 
Daly, & O’Donovan 2012; Jeste & Geschwind 2014; Happé, Ronald, & Plomin, 2006).  The 
broad phenotype of ASD has made it difficult to classify using behavioral diagnostic rubrics 
(Tsai and Ghaziuddin 2013; Young and Rodi 2013). The recent transition from the DSM-IV-TR 
to the DSM-5 involved significant changes to the categorization of ASD, and were in part 
motivated by the heterogeneity of the disorder. While the DSM-IV provided separate diagnostic 
criteria for Autistic Disorder, Asperger’s Disorder and Pervasive Developmental Disorder Not 
Otherwise Specified, the DSM-5 realigns these categories into one umbrella diagnosis – ASD.  
The unification of this diagnostic criteria has been met with some resistance from 
researchers who support the discrete categories of the DSM-IV-TR, arguing they identify 
clinically useful subgroups (Tsai & Ghaziuddin 2013). A survey of the literature does reveal 
some distinct phenotypes between the DSM-IV-TR categories (Tsai & Ghaziuddin 2013), but 
advocates of the DSM-5 criteria cite broad overlap of symptoms and the absence of evidence for 
distinct biological etiologies to justify the spectrum model (Young & Rodi 2013). Those who 
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favor the DSM-5 changes do not endorse a homogeneous view of ASD, but instead argue that 
discrete categories without biological justification are invalid (Young & Rodi 2013). In this case, 
no categories are better than false categories. Broad support exists on both sides of the debate 
that ASD is a heterogeneous disorder, the disagreement is simply around what role biological 
considerations should play in diagnosis (Tsai & Ghaziuddin 2013; Young & Rodi 2013).  
 While the DSM-5 has taken an important step in abandoning discrete categories not 
supported by biological research, more work needs to be done to identify clinically useful 
subgroups of the autism spectrum. The most promising behavioral research with this goal 
proposes developmental trajectories, which account for individual change over time, as a 
potential method for dividing ASD into meaningful subgroups (Venker et al., 2014). Foss-Feig et 
al. (2016) make the most explicit endorsement for this transition and argue that a model which 
clusters symptoms along positive, negative and cognitive features would help capture 
development over time.  More traditional models of lifespan development have also been 
suggested as suitable for the purpose of generating developmental trajectories for ASD (Franklin 
et al., 2015). In both cases authors are advocating for perspectives in which ASD is flexible, not 
only in terms of symptom severity, but also in terms of change over time. 
 Developmental trajectories based on behavioral data have the advantage of incorporating 
clinical concerns into what would otherwise a science of taxonomy. By collecting and examining 
longitudinal behavioral data, researchers can explore which factors in early development are 
associated with better or worse outcomes, as well as responsiveness to intervention. Statistical 
methods such as group-based trajectory modeling have been employed to identify subgroups of 
the autism spectrum based on changes in symptomatology over time (Fountain, Winter, & 
Bearman, 2012). This research, however, does not address the critical issue of identifying 
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individuals with ASD who experience poor outcomes and do not respond favorably to treatment. 
Serious engagement with the research around treatment of ASD highlights these concerns and 
has informed important research on developmental trajectories in ASD.  
Current State of Clinical Treatment. 
 Pharmacological. 
 Medical intervention for individuals with ASD involves the use of prescription 
medication. Two of the most commonly prescribed medications for ASD are risperidone and 
aripiprazole. Both are atypical antipsychotic medications that are used to treat irritability in 
children with ASD and have been shown to be effective in this treatment (Aman et al., 2015; 
Maloney, Mick, & Frazier, 2014). A comparison of the studies supporting the use of these 
medications found similar effectiveness between aripiprazole and risperidone, with each 
possessing similar secondary effects such as weight gain, sedation and extra pyramidal syndrome 
(Cohen et al., 2013). New medications, such as arbaclofen, are currently being researched as 
alternative treatments for aggression in individuals with ASD that may avoid unwanted 
secondary effects (Erickson et al., 2014).  
Oxytocin is being researched as a possible medication for the treatment of core symptoms 
of ASD, as opposed to treating aggressive behavior like atypical antipsychotics. While there is 
some evidence that risperidone can improve the social functioning in children with ASD, this is 
likely a result of the primary effect of this drug decreasing aggressive behaviors (Aman et al., 
2015). Oxytocin was initially considered as a possible treatment for ASD due to the role it 
played in modulating similar symptoms in animal models (Stohn et al., 2018; Štefánik, Olexová, 
& Kršková, 2015). While Oxytocin appears to have fewer secondary effects compared to 
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atypical antipsychotics, the current research does not demonstrate meaningful effectiveness for 
the core symptoms of ASD (Cai, Feng, & Yap, 2018; Keech, Crowe, & Hocking, 2018) 
 While atypical antipsychotic medications are effective in treating aggressive symptoms 
and irritability in individuals diagnosed with ASD, they occur with serious secondary effects, 
and are not effective at treating the core symptoms of ASD. Oxytocin has been proposed as a 
possible treatment for the core symptoms of ASD, but research has yet to demonstrate this 
effectiveness. There are also no known cures for the ASD (Bölte, 2014). In the absence of 
effective pharmacological interventions, behavioral treatment has become the primary method 
for improving outcomes of individuals with ASD. 
 Applied Behavioral Analysis. 
The first treatment to consider when looking at interventions for ASD is Applied 
Behavioral Analysis (ABA). This treatment is considered the first-line therapy for ASD and is 
the most empirically validated treatment program for ASD (Magiati, Tay, & Howlin, 2012; 
Munshi et al., 2011).  ABA therapy was developed through the 1970’s and 80’s by Dr. Lovaas 
and was originally described as the “Lovaas Method” (Dillenburger & Keenan, 2009; Lovaas, 
1987).  This treatment method evolved out of B.F. Skinner’s work on behaviorism and proceeds 
by controlling the client’s environment in order to elicit desired behavior. This treatment follows 
the stimulus-response model of human behavior and shapes patient’s behaviors by imposing a 
system of reward and punishment for desired and undesired behaviors (Bondy, Esch, & 
Sundberg, 2010).   
ABA treatment is developed according to an individual needs assessment.  The 
behavioral needs assessment is traditionally done by administering a behavioral instrument such 
as the Verbal Behavior Milestones Assessment and Placement Plan (VB-MAPP) which indicates 
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the level of functional behavior of patients (Sundberg, 2008).  This assessment provides a 
template from which therapists develop the initial behavior plan, which targets specific behaviors 
for increase or decrease, and outlines the intervention protocols for each behavioral goal.  
Specific behavior goals can range – from a child remaining seated for a period of time, to 
answering WH questions (who, what, where and when) effectively, to decreasing self-injurious 
behavior.  The protocols for achieving each goal can vary, but the most common is Discrete Trial 
Training (DTT), which consists of presenting a patient with a specific task and rewarding 
appropriate behavior (Magiati, Tay & Howlin, 2012). Rewards are labeled “reinforcers” since 
ideally, they reinforce preferred behaviors. As ABA therapy progresses, goals are revised 
depending on the progress of an individual patient.  Behavioral data is taken over a series of 
sessions and informs a behavioral therapist’s judgment regarding the need to adjust goals or 
treatment protocols.  
Reliance on DTT has waned in recent years as new methods of ABA have been 
developed. Pivotal Response Treatment (PRT) and Early Start Denver Model (ESDM) are two 
methods of behavioral treatment which rely on identifying goals for children and using 
behavioral reinforcement techniques to achieve those goals. PRT is distinguished from DTT 
because goals are areas of development, such as motivation and social initiation, as opposed to 
discrete behaviors (Duifhuis et al., 2017). Research has demonstrated the effectiveness of PRT in 
improving functioning for children with ASD in the domains of socialization, communication, 
and daily living skills (Ventola et al., 2014; Ventola et al., 2016; Duifhuis et al., 2017). As with 
all forms of ABA, however, responsiveness to PRT is not consistent across all participants and 
researchers are looking for markers that might identify those who are less responsive to 
intervention (Fossum, Williams, Garon, Bryson, & Smith, 2018). Research into this modality has 
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incorporated neural measurements which may help identify treatment resistant subrgoups of 
ASD (Ventola et al., 2015). 
ESDM involves more parent participation than other ABA methods and allows therapists 
to work on developing interpersonal relationships with their clients (Ryberg, 2015). The 
effectiveness of this approach has provided practitioners with another viable method for treating 
ASD (Dawson et al., 2010). Most noteworthy about the ESDM approach, however, is that is 
demonstrated the importance of timing and intensity of behavioral intervention. Behavioral 
treatment of children with ASD is most effective when it is intensive, at least 20 hours of 
intervention a week, and delivered as early as possible, even for children as young as 12 months 
of age (Rogers et al., 2012). Benefits of early and intense intervention have been replicated with 
other ABA techniques and is not restricted to ESDM (Elder, Kreider, Brasher, & Ansell, 2017). 
The importance of early intervention has impacted clinical approaches to diagnosis, since better 
outcomes are associated with earlier treatment, clinicians have started to provide effective 
methods for early diagnosis (Vietze & Lax, 2018). The Autism Diagnostic and Observation 
Schedule was revised in 2012 to include a new toddler module, which allows for the earlier 
detection of ASD, even among children as young as twelve months of age.  
Treatment Outcomes and Effectiveness. 
Quality of life for individuals diagnosed with ASD is significantly lower than their 
typically developing counterparts (van Heijst & Geurts, 2015), and the majority of children 
receiving the diagnosis will likely require lifelong care (Billstedt, Gillberg & Gillberg, 2005).  In 
one of the largest samplings to explore the question of outcomes for individuals with ASD, 
researchers found that 58% of participants had ‘Poor’ or ‘Very Poor’ outcomes in terms of 
employment, independent living, friendships, and language ability (Howlin, Goode, Hutton, & 
ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD  15 
 
Rutter, 2004). Poor outcomes were most strongly correlated with low verbal IQ (<70) even 
though participants with verbal IQ’s below 50 were excluded from this study. These outcomes 
appear to be the result of variable responses to treatment, rather than a necessary outcome of the 
disorder. 
Although intense, early intervention ABA is the most empirically validated treatment for 
ASD (Peters-Scheffer et al., 2011) portions of the population continue to respond less favorably 
than others (Eikeseth, 2009). This variable responsiveness has led researchers to look for patient 
factors that may predict outcomes of behavioral intervention. While researchers continue to 
examine behavioral profiles to answer this question, two factors have achieved consensus in 
terms of their impact on treatment responsiveness, namely, verbal IQ and early intervention 
(Peters-Scheffer et al., 2011). Access to early and intensive behavioral intervention has been 
shown to be a necessary condition for positive outcomes in individuals with ASD, and these 
findings have influenced social policy to increase provision of these services to families. The 
impact of verbal IQ on treatment outcomes has been more problematic, particularly because this 
feature is difficult to measure in young children receiving early and intensive behavioral 
intervention. 
Developmental trajectories which incorporate clinical considerations have also 
highlighted the importance of verbal IQ when identifying outcomes in adults with ASD. The first 
study of this kind used longitudinal data to show that outcomes at age 19 of children diagnosed 
with ASD was strongly predicted by verbal IQ at age 2 or 3. In particular, individuals with verbal 
IQs below 70 were found to have poor outcomes in 85% of cases (Anderson, Liang, & Lord, 
2014). Additional research using similar methods has replicated these findings, showing that 
grouping individuals with ASD into low and average IQ groups, based upon a verbal IQ 
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benchmark of 70, strongly predicts outcomes in later life (Lord, Bishop, & Anderson, 2015). 
These findings were also replicated in a study with a dividing point of verbal IQ at 85 (Kim, Bal, 
& Lord, 2018). These crucial findings provide a starting point for researchers interested in 
identifying early biomarkers that could detect treatment resistant subgroups of ASD. 
Purpose of this Study 
The purpose of our study is to investigate a potential biomarker that could distinguish 
individuals with autism and low verbal IQ from their average verbal IQ, and typically 
developing, counterparts. The analysis we propose attempts to distinguish these groups within a 
sample of children age four to eleven-years-old, when IQ is considered more stable and measures 
of verbal IQ are more reliable. The utility of this biomarker, however, would ultimately be found 
in its application to distinguish these groups in toddlerhood, when treatments are first introduced 
and there is a need for early identification of treatment resistant subgroups. For this reason, we 
have chosen a biomarker which has demonstrated its effectiveness at identifying ASD among 
toddlers. 
Bosl et al. (2011) demonstrated that sample entropy analysis of resting state EEG signals 
could effectively distinguish a group of children at high risk for autism, due to a sibling 
diagnosis, and healthy controls. Participants in the study were between 6 and 24 months old, with 
the most significant findings for children between 9 and 12 months of age. Sample entropy 
measurements have the potential to aid in early diagnosis of ASD as indicated by Bosl et al. 
(2011). However, the most pressing clinical need for this population is the early detection of 
individuals who do not respond as well to behavioral intervention and have worse outcomes in 
adolescence and adulthood. The purpose of our study is to examine whether sample entropy is 
able to identify this group in a sample of children between the ages of four and eleven. 
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Research Questions 
 The analysis presented in our study proceeds in two parts. The initial analysis sheds light 
on the sample by examining the cognitive profiles of participants, and the relationship between 
demographic factors, such as sex and age, with scores on behavioral measures. The second phase 
of the analysis introduces sample entropy, and this is where our research questions are posed. 
Our first research question – is sample entropy correlated with measures of ASD symptoms, IQ, 
and adaptive functioning? – is addressed in a correlational analysis between sample entropy 
measurements and scores on the ADOS-2, DAS-II, and Vineland-II. Our second research 
question – can sample entropy distinguish Typ, ASDAvg, and ASDLow groups? – is addressed 
through an ANOVA analysis of sample entropy measurements between these groups. Additional 
considerations addressed by our research are covered in the “Discussion” section of this paper, 
however, the above are our two primary research questions. 
Relevance of this Study 
 The relevance of this study comes from the introduction of biological measures to 
improve our understanding of ASD. Research into the biological underpinnings of ASD is part of 
a broader movement to define disorders through physiological measurements, embodied most 
concretely in the RDoC project (Insel, et al., 2010). Our research builds on previous research by 
Bosl, et al., (2011), which has demonstrated that sample entropy is effective at distinguishing 
children at high risk of ASD from typically developing counterparts. It could be argued that the 
relevance of our study is derived from the extension of this method is an attempt to broaden our 
understanding of ASD from a biological perspective. 
 More importantly, however, this study uses biological measures to address a pressing 
clinical need in the field of ASD research. The goal of this study is to use the method of sample 
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entropy analysis identified in Bosl, et al. (2011) to distinguish low verbal individuals with ASD 
from their high verbal, and typically developing, counterparts. If this method has the ability to 
distinguish these groups, then it is possible that clinicians could identify treatment resistant ASD 
in infancy. This would allow clinicians and researchers to develop and test alternative treatments 
with the goal of improving outcomes for those with the highest need on the autism spectrum.  If 
our study shows promise, then sample entropy would be a worthwhile measure to incorporate 
into longitudinal studies on ASD, to improve our understanding of biological measures in the 
context of change over time. 
Defining Entropy 
Entropy has different definitions depending on the discipline in which it used, most 
notably thermodynamics and information theory. The use of entropy, or sample entropy, in our 
study is more closely aligned with the definition of the term used in information theory. Here, 
entropy was first defined by Claude Shannon in a paper titled A Mathematical Theory of 
Communication (1948). Entropy in information theory is defined as a measure of uncertainty 
determined by the probability of possible outcomes. Under this definition, the outcome of a dice 
roll has greater entropy than the flip of a coin, since the dice roll resolves uncertainty related to 
six possible outcomes and the coin flip resolves uncertainty related to two possible outcomes.  
One of the earliest applications of entropy in describing a sequence of events occurred in 
Claude Shannon’s living room with his wife, Betty. They observed together that, when provided 
the first few words of a sentence in English, subsequent words became easier and easier to guess. 
That is to say, the uncertainty of guessing possible words early in a sentence in English is greater 
than the uncertainty of guessing words later in that same sentence (Horgan, 2016). Information 
theory has transformed the observations made in the Shannon’s living room into a science which 
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characterizes the nature of information in communication systems such as English, as well as 
those found in the natural world. 
Costa, Goldberger, and Peng (2005) applied information theory and the concept of 
entropy to biological signals, looking specifically at cardiac rhythms. These researchers found 
that the complexity of biological signals generated by the heart were an indicator of advanced 
age, atrial fibrillation, and congestive heart failure. Complexity in this study was measured by 
multiscale entropy, which analyzed time series data generated by cardiac rhythms and examined 
how frequently pairs of data points were replicated in the remaining sequence. Signals which 
were highly ordered and regular, where pairs of data points were replicated frequently 
constituted a signal with less complexity and lower entropy. These patterns were more 
commonly associated with pathological heart conditions. In contrast, signals that were less 
regular were associated with healthier heart conditions. Considered from the perspective of 
entropy, the more regular cardiac rhythms can be said to contain less uncertainty because data 
later in the sequence can be more accurately predicted based upon data early in the sequence. 
Signals with more complexity have higher entropy because there is greater uncertainty about the 
position of data later in the sequence, based upon knowledge of data early in the sequence. 
Bosl et al. (2011) applied the method developed by Costa, Goldberger, and Peng (2005) 
to EEG signals in order to distinguish a group of children at high risk of ASD from typically 
developing peers. This method is the basis of our study. Other researchers have used measures of 
entropy in neuroscience, most notably identifying entropy within fMRI data as a possible 
indicator of intelligence (Saxe, Calderone, & Morales, 2018). The use of sample entropy to 
identify a subgroup of ASD with low verbal ability, as proposed in our study, is part of an 
expanding use of entropy within the neuroscience research community. 




 The data for our study was retrieved from the National Database for Autism Research 
(NDAR), which is an NIMH Data Archive. This data archive serves as a repository for de-
identified, research participant data made available to the wider research community. 
Researchers can access participant data based upon search parameters, which return appropriate 
collections of client data. This is a useful mechanism for researchers interested in meta-analytic 
studies because it does not impede cross-study comparisons. For our purposes, however, it was 
necessary to find a single study with the relevant participant data, because a small sample was 
more suited to the pilot study we were pursuing. 
 A preliminary review of research in NDAR generated five candidate studies which had 
collected data appropriate for our research. The data required for our study was, EEG 
measurements, IQ tests (either WAIS or DAS), ADOS scores, and Vineland scores. Five studies 
had performed research which included this data. Ultimately, we selected the Autism Biomarkers 
Consortium for Clinical Trials (NDAR #2288) as our data source because it had the appropriate 
number of participants (51), the subject records were largely complete (forty-nine of the fifty-one 
participants had EEG, IQ, ADOS, and Vineland data), and EEG data was the appropriate length 
(resting state measurements were about one minute long). There were also multiple resting state 
EEG measurements in case of bad electrodes or eye movement artifacts. This study collected 
three resting state measurements taken on two visits, for a total of six possible data points. EEG 
data files were also in Matlab format, which was conducive to our proposed analysis. 
 The Autism Biomarkers Consortium for Clinical Trials is an investigation led by James 
McPartland at Yale University and its principle aim is to collect EEG, eye tracking(ET), 
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intelligence, and social impairment data to identify biomarkers which may help stratify the 
currently heterogeneous category known as ASD into subgroups. Assessments in this study were 
conducted at three timepoints, including baseline, 6 weeks and 24 weeks. The ADOS-2, DAS-II 
and Vineland-II were only administered at baseline, but EEG, ET and social impairment 
measures were administered at all time points. Participant data was made available through 
NDAR with the help of the Data Acquisition and Analysis Core. The rationale and methodology 
of the study is outlined in McPartland (2017). 
Participants 
 This Autism Biomarkers Consortium for Clinical Trials recruited typically developing 
children and children diagnosed with ASD between 4 and 11 years of age. Participants were 
recruited at five sites throughout the Unites States – Boston Children’s Hospital, Duke 
University, UCLA, University of Washington, and Yale Child Study Center. While enrollment in 
this study is ongoing, at the time of our analysis there were fifty-one participants with data 
available through NDAR. Participant demographics and cognitive profiles are considered in 
more detail at the beginning of the “Results” section. 
Procedures 
For our research, data from NDAR study #2288 was accessed, downloaded, and cleaned 
using Matlab code. The data tables provided by NDAR contained numerous redundancies and 
omissions when initially accessed. Redundancies were eliminated and omissions were 
standardized in the cleaning of this data. Relevant scores from the ADOS-2, DAS-II, and 
Vineland-II were organized by participant for our analysis. Participant groups were divided by 
diagnostic categories and verified using ADOS-2 comparison scores. Participant groups were 
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further refined by identifying a “Low Verbal” subgroup of children diagnosed with ASD who 
had verbal IQ scores below 85. 
The Autism Biomarkers Consortium for Clinical Trials collected EEG data using a 
Clinical Geodesic EEG System 400 with 128 electrodes. A map of electrode locations for this 
system is included in Appendix A. For our analysis of sample entropy, fewer electrode sites were 
required and we selected the most commonly used 19 sites, including C3, C4, O1, O2, Cz (Ref in 
Appendix A), F3, F4, F7, F8, Fz, Fp1, Fp2, P3, P4, P7, P8, Pz, T7, T8. The 1000 Hz sampling 
rate of the Clinical Geodesic EEG System 400 allowed for an analysis of sample entropy at six 
frequencies, High Gamma, Gamma, Beta, Alpha, Theta, Delta. 
Sample entropy was calculated within these frequencies at each of the nineteen scalp 
locations recorded for participants, resulting in one hundred and fourteen sample entropy 
measurements per participant. This method of identifying sample entropy was first identified by 
Costa, Goldberg, and Peng (2014), and can be applied to any physiological data represented as a 
time series, traditionally EEG and EKG data. This method for determining sample entropy has 
been adapted and modified by subsequent researchers, most notably in the study distinguishing 
typically developing infants from those at high risk of ASD. The sample entropy measurements 
for our study follows the method developed in this study. (Bosl, et al., 2011) 
Measures 
The behavioral measures selected for our study are the ADOS-2, DAS-II, and Vineland-
II. The ADOS-2 comparison score was used to confirm ASD diagnosis and distinguish the 
control group and children diagnosed with ASD. The DAS-II was used to identify children with 
verbal IQ scores lower than 85. Additional scores provided by the ADOS-2 and DAS-II were 
included in our initial analysis to present a complete picture of the sample. The Vineland-II was 
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also included to present adaptive behavior profiles of participants, and ensure that the expected 
correlations between ASD severity, IQ scores, and adaptive functioning were intact for this 
sample. Below is a summary of the three measures used. 
ADOS-2. 
The ADOS-2 is an assessment instrument used for the diagnosis of ASD. It consists of 
standard activities for clients which allow the assessor to observe behaviors relevant to ASD 
diagnosis (Lord, et al., 2012). Many of the activities used in the ADOS are planned social 
activities designed specifically to create a context where the communicative and social 
impairments of ASD become apparent. The assessment may be administered to anyone over 12 
months of age and there are five modules for clinicians to select between. Each module contains 
a list of activities designed for different ages and verbal ability. The toddler module can be 
administered to children between 12 and 30 months of age. It consists of simple social 
interaction that does not require verbal ability, such as passing a ball back and forth with the 
assessor and presents the child with cause-and-effect toys which often elicit restricted and 
repetitive behavior.  Modules 1-4 present activities appropriate for older children and adults. 
Module 4 consists largely of conversation where the assessor asks the client to discuss topics 
such as friendship, emotional attunement, and social difficulties, among others. Tactile activities, 
such as a spinning disk, are also presented to explore potential repetitive and restrictive behavior. 
 Each module of the ADOS-2 is scored in a similar fashion. The assessor takes careful 
observational notes during the assessment and provides the client with a score between 0-3 in a 
number of domains. Zeros are given for typical behavior, and threes for behavior consistent with 
ASD. For example, in Module 4 domain A10, Emphatic or Emotional Gestures a 0 is given when 
a client exhibits “a range of appropriate emphatic and/or emotional gestures that are well 
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integrated with speech,” and a 3 is given when there is “no or very limited emphatic or emotional 
gestures.” (Lord, et al., 2012) The algorithm for diagnosis selects those domains which 
distinguished typically developing children from children with ASD in the validation sample. A 
sum of scores in these domains is converted to a comparison score between 1 and 10. The 
modules are aligned so that a comparison score of 4 in any module is considered consistent with 
a diagnosis of ASD. 
 The ADOS-2 can be administered by clinical psychologists and physicians with prior 
education, training, or experience with the instrument. (Lord, et al., 2012) The Autism 
Biomarkers Consortium for Clinical Trials administered the ADOS-2 for every client and the 
scores are considered valid for our purposes. Participants in our study were distinguished into 
typically developing and ASD groups by clinical diagnosis, and each participant was verified as 
having an ADOS-2 comparison score of 4 or greater.  
 Validity and reliability for the ADOS-2 built upon previous studies of the original ADOS 
since many of the items and administration remained the same. The ADOS-2 extended validation 
sample contained 1,415 individuals and 2,195 assessments. While the toddler module was 
introduced in the ADOS-2, our study only relied on administration of modules 1, 2, and 3. 
Interrater reliability of items within the validation sample had an exact reliability of 91.5%, 89%, 
and 88.2% for modules 1, 2, and 3 respectively. Test-retest reliability was .87, .83, and .87 for 
module 1, 2, and 3 over the course of 10 months, with much of this change attributed to the 
effects of behavioral intervention. Item validity and their correlation with ASD diagnosis 
remained largely consistent between the ADOS and ADOS-2, however, new diagnostic 
algorithms were developed to increase sensitivity of the instrument to the verbal ability of 
children. For example, module 1 contains two algorithms for children based on their ability to 
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produce five or more words during the assessment. Children able to produce more words receive 
higher Comparison scores based on fewer symptoms, because children with lower language 
abilities naturally produce more autistic-like symptoms to facilitate their social communication. 
Additional items that do not factor into diagnostic scores, such as “Anxiety” and “Overactivity”, 
are included in the assessment, because they can influence behavior observation during the 
assessment.  
DAS-II. 
The DAS-II is composed of cognitive batteries that measure verbal ability, nonverbal 
reasoning, and spatial ability. The Early Years battery can be administered to children between 
the ages of two and a half and six years eleven months. The School-Age battery can be 
administered to children between seven and eighteen years of age. The division of batteries 
allows for flexibility in administration so that older children with lower ability may be 
administered the Early Years battery, while younger children with greater ability may be given 
the School Age battery (Elliott, 2007). 
 The DAS-II General Conceptual Ability (GCA) score is derived from the three cluster 
scores – verbal, nonverbal, and spatial ability – and is a measure of psychometric g, often 
referred to as intelligence or IQ. The author of the DAS-II, however, finds the labels 
“intelligence” and “IQ” problematic, and stresses the value of cluster scores over the GCA. Each 
cluster is a homogeneous assessment of a particular component of g, with verbal ability 
measuring crystallized intelligence, nonverbal reasoning measuring fluid reasoning, and spatial 
ability measuring visual processing and visual-spatial ability. (Elliott, 2007) Therefore, 
interpretation of cluster scores, and their differences, provides a more nuanced picture of a 
child’s cognitive profile when compared to the single GCA score. While the Autism Biomarkers 
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Consortium for Clinical Trials uses the DAS-II as a measure of intelligence, and the term “IQ” is 
commonly used in the literature we reviewed, our individual analysis is more in line with the 
method of interpretation advocated by the author of the DAS-II, since we rely on the Verbal 
Ability score rather than the GCA to differentiate participant groups. 
 Like the ADOS-2, the DAS-II is the second iteration of an established psychometric 
assessment and builds upon its predecessor to establish reliability and validity. Intercorrelations 
between subtests of the DAS-II support the conclusion that distinct, but related abilities, are 
measured by the instrument. Factor analysis of DAS-II scores indicated that the number of 
cognitive abilities measured by this instrument increased with age, consistent with findings in the 
original DAS sample. This development supported the division of the DAS-II into the Early 
Years and School Age subtest. External validity of the DAS-II was established through a 
comparison with other measures, most notably the Wechsler Intelligence Scale for Children, 
Fourth Edition, with correlations between GCA-Full scale IQ, Verbal Ability-VCI, and SNC-PRI 
being .84, .73, and .77 respectively. 
Vineland-II. 
 The Vineland-II is a measure of adaptive functioning commonly used to assess an 
individual’s ability to manage the practical requirements of daily life. It measures functioning in 
the domains of Communication, Daily Living Skills, and Socialization. The Communication 
domain assesses receptive, expressive and written language skills, Daily Living Skills assesses 
personal, domestic, and community skills, and Socialization measures interpersonal relationship, 
play and leisure, and coping skills. (Sparrow, Cicchetti, & Balla, 2005) The domain scores are 
combined to provide an Adaptive Behavior Composite score, which estimates overall adaptive 
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functioning. Additional domains assessing motor skills and maladaptive behaviors can also be 
administered. 
 The Vineland-II is frequently used as a measure of adaptive functioning for children with 
ASD. Adaptive functioning is a particularly useful area for assessment because it identifies 
barriers individuals may encounter as they work towards independent living. Along with 
diagnostic instruments such as the ADOS-2, and IQ measurements such as the DAS-II, the 
Vineland-II is administered to individuals with ASD to provide a more complete picture of their 
behavioral profile. When new instruments are developed for assessing individuals with ASD, the 
Vineland-II is often included to demonstrate correlations between established measures and the 
proposed instrument (Craig et al., 2017). 
 The Autism Bioarkers Consortium for Clinical Trials provided results of the Vineland-II 
assessment for all participants in the NDAR database. The adaptive profiles of participants 
included the three domains scores as well as the Adaptive Behavior Composite. Our study 
included Vineland-II scores to generate a more complete picture of participants behavioral 
profile.  
Data Analysis Plan 
 The data collected for our study was processed according to the Matlab code presented in 
Appendix A. The first step in the research process was to import the data from NDAR, clean the 
data, standardize values, organize data across measures by participant, and separate participants 
into typically developing (Typ), ASD with average verbal ability (ASDAvg), and ASD with low 
verbal ability (ASDLow) groups. While the more common point of division between average and 
low verbal ability is a verbal IQ of 70, two standard deviations below the norm (Lord, Bishop, & 
Anderson, 2015; Anderson, Liang, & Lord, 2014), our sample contained only two participants in 
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the lower category using this metric. To remedy this problem, we used a dividing score of verbal 
IQ 85, one standard deviation below the norm, which raised our participant number in this group 
to eight. This method of grouping has also been used in studies which identified low functioning 
subgroups of ASD (Kim, Bal, & Lord, 2018). 
The second step involved an analysis to determine the cognitive profiles and 
demographic features of the sample, looking specifically at the effects of sex and age on the 
sample. The third step was a correlational analysis examining the relationship between 
behavioral measure scores, including the ADOS-2, DAS-II, and Vineland-II.  The fourth step 
included participant’s sample entropy measurements and examined the correlation between 
sample entropy and scores on behavioral measures. The fifth and final step was an ANOVA 




The psychological scores of subjects in this study indicate a wide range of abilities in 
adaptive functioning, levels of intelligence and presence of autistic symptomatology. Table 1 
presents a summary of the scores for scales and subscales on the ADOS-2, DAS-II and Vineland-
II. These scores depict the wide variety of cognitive profiles present in the current sample. 
Verbal intelligence, for instance, ranges from the very high at 148 to very low at 30. The ADOS-
2 Comparison scores range from 0, suggesting no autistic symptomatology to 10, the highest 
possible score on this measure. The Vineland-II Communication subdomain scores span from the 
Low range at 42 to the High range at 130. These scores indicate that a variety of cognitive 
abilities occur within this sample and suggest that, although the sample size is limited, it has 
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captured the diverse cognitive presentations in the wider population of typically developing 
children and children diagnosed with ASD. 
Table 1 
Summary of Subject Age Distribution and Assessment Scores 
 
Within the sample we found that there are strong correlations between domains of 
intelligence, adaptive functioning and autistic symptomatology. Correlations between subscales 
of individual measures are to be expected and reflect the internal consistency of well-developed 
psychological testing instruments. The correlations between measures, however, indicate that 
abilities were consistent across domains. For example, in our sample, strengths in intelligence 
were correlated with higher levels of adaptive functioning and lower levels of autistic 
symptomatology, while higher levels of autistic symptomatology were correlated with lower 
adaptive functioning and IQ scores. A full correlational analysis between subscales of the 
psychological measures are provided below in Table 2. For each correlation coefficient listed 
there is a related p-value below .05, with blank cells having nonsignificant correlations. 
 
 
Row Min Max Mean Standard_Deviation
Age 49 138 87.81632653 26.5021017
ADOS_SA 0 17 5.897959184 5.792397668
ADOS_RRB 0 8 1.734693878 2.233975438
ADOS_Total 0 23 7.632653061 7.460154929
ADOS_Comparison 1 10 4.265306122 3.480753691
IQ_Verbal 30 148 104.4081633 21.03560312
IQ_Nonverbal 55 133 105.6041667 14.99040769
IQ_Spatial 46 136 101 16.23890783
IQ_GCA 42 133 104.9787234 18.2178715
IQ_SNC 42 124 104.1041667 15.28069229
Vineland_Comm 42 130 95.44897959 21.93746911
Vineland_DLS 45 121 90.08163265 17.22018769
Vineland_Soc 57 118 90.28571429 18.41760933
ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD  30 
 
Table 2 
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 The strongest correlations occur between subscales of the same measure, as we might 
expect.  There are some interesting correlations between measure subscales, most notably the 
ADOS-2 subscales and Vineland-II subscales. Total ADOS-2 scores are correlated with the 
Vineland-II Communication and Socialization scores at -.78 and -.79 respectively. DAS-II 
subscale correlations are more modest, with the Verbal, Nonverbal, Spatial and GCA correlated 
with ADOS Total scores at -.61, -.43, -.62 and -.66 respectively. These correlations are intuitive 
since the adaptive functioning scales of communication and socialization measure behavior more 
closely aligned with the core features of ASD, in contrast to intelligence measures. 
 An additional noteworthy feature of Table 2 is the age column and its correlational 
coefficients. This column was included because, unlike Sex which is binary, age is a continuous 
measurement which can be easily compared to a range of scores provided by psychological 
measurements. In Table 2, age has a correlation of .33, .30 and .38 with the Social Affect, Total 
and Comparison scores of the ADOS-2, respectively. These correlations are important because 
they explain the significant difference in age we find between our sample subgroups, described 
below. The significant relationship between age and autistic symptoms in our sample presents a 
possible confound in our final analysis, and is important to keep in mind. 
 When we divide our sample into three groups, Typ, ASDAvg, and ASDLow we find 
significant differences in group performance across measures. Tables 3, 4 and 5 provide t-test 
comparisons between Typ-ASDAvg, Typ-ASDLow and ASDAvg-ASDLow respectively. We 
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Table 3 
Summary of T-Tests Between Typically Developing Children, and Children with ASD and 
Average Verbal IQ 
 
Table 3 reviews the results of t-tests comparing psychological scores of the Typ group 
compared with the ASDAvg group. The pervasive differences across virtually every domain is 
striking. While differences in ADOS scores are predictable, what is interesting about this 
comparison is that the ASDAvg group has, in some ways, controlled for intelligence by 
removing those subjects with low verbal IQ. Nevertheless, we find that there remain significant 
differences in all domains of intelligence apart from nonverbal IQ. This may be due to the 
elevated IQ scores of the Typ group as we see in their mean GCA of 114. This is nearly a full 
standard deviation higher than we would expect of a normal sample of typically developing 
children. On the one hand, this presents challenges related to the generalizability of our study 
and on the other hand it increases differentiation in performance between groups based on the 
metric we hope to quantify through EEG sample entropy. These considerations will be explored 
more fully in the discussion section of this paper. 
 
Row T_test p_value Typ Mean Typ Stand_Dev ASDAvg Mean ASDAvg Stand_Dev
Age 1 0.009492594 79.84615385 23.93272623 101.3125 26.16287127
ADOS_SA 1 2.69482E-14 1.153846154 1.222859197 10.625 3.913651322
ADOS_RRB 1 6.75654E-07 0.192307692 0.491465626 3 2.366431913
ADOS_Total 1 4.92593E-17 1.346153846 1.354763675 13.625 4.145278439
ADOS_Comparison 1 1.97056E-21 1.192307692 0.401918476 7.6875 1.701714821
IQ_Verbal 1 0.004574464 115.2307692 13.79364402 102.125 13.61800279
IQ_Nonverbal 0 0.360184567
IQ_Spatial 1 0.005838726 108.7692308 10.69320417 97.9375 13.21851605
IQ_GCA 1 0.002452185 114.0769231 9.337764516 103.8 10.53700961
IQ_SNC 1 0.008059528 111.0384615 8.032338485 102.875 10.89877669
Vineland_Comm 1 1.55032E-08 111.2692308 14.27041048 80.9375 12.1735711
Vineland_DLS 1 9.59943E-05 100.3461538 13.95691171 82.75 10.5229907
Vineland_Soc 1 9.51556E-09 103.5769231 12.1759536 76.125 11.64402565
Sex 0 0.119002227
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Table 4 
Summary of T-Tests Between Typically Developing Children, and Children with ASD and Low 
Verbal IQ 
 
The results displayed in Table 4 are largely consistent with those displayed in Table 3. As 
we would expect, the differences between Typ and ASDLow are more significant than those 
between Typ and ASDAvg, which now includes nonverbal IQ. What is interesting to note about 
these two groups is the absence of any significant difference based upon age. As opposed to the 
Typ-ASDAvg comparison which did yield a significant difference based on age, the Typ-
ASDLow groups are not significantly different by age. This further analysis suggests that the 
correlation between ADOS scores and age observed in Table 2 may be explained by the 
disproportionately high age of the the ASDAvg group. As with the unusual IQ scores among the 
Typ group discussed above, the differences in age within our sample poses some challenges with 




Row T_test p_value Typ Mean Typ Stand_Dev ASDLow Mean ASDLow Stand_Dev
Age 0 0.526767
ADOS_SA 1 3.87467E-15 1.153846154 1.222859197 12.71428571 3.545621042
ADOS_RRB 1 4.73035E-17 0.192307692 0.491465626 4.571428571 0.975900073
ADOS_Total 1 6.51288E-17 1.346153846 1.354763675 17.28571429 4.34796066
ADOS_Comparison 1 8.28383E-21 1.192307692 0.401918476 7.857142857 1.345185418
IQ_Verbal 1 3.41376E-08 115.2307692 13.79364402 69.42857143 18.29259543
IQ_Nonverbal 1 0.000136451 110 11.65160933 84 18.86796226
IQ_Spatial 1 7.06561E-07 108.7692308 10.69320417 75.5 16.08415369
IQ_GCA 1 2.76346E-10 114.0769231 9.337764516 68.5 16.58613879
IQ_SNC 1 1.62968E-07 111.0384615 8.032338485 77.33333333 20.02664891
Vineland_Comm 1 1.44043E-07 111.2692308 14.27041048 69.85714286 14.85966096
Vineland_DLS 1 6.05433E-06 100.3461538 13.95691171 68.71428571 12.29788987
Vineland_Soc 1 1.39492E-06 103.5769231 12.1759536 73.28571429 10.93487213
Sex 0 0.698519558
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Table 5 
Summary of T-Tests Between Children with ASD and Average Verbal IQ, and Children with ASD 
and Low Verbal IQ 
 
Table 5 presents a comparison of psychological scores between the ASDAvg and 
ASDLow groupings. These t-tests are consistent with the broader analysis and demonstrate no 
significant differences within ADOS scores, although the ADOS-2 total scores approach 
significance. The ADOS Comparison scores, which can be used to determine ASD severity, are 
not significantly different. The ASDAvg and ASDLow groups are significantly different on 
every IQ scale, which is to be expected given that the ASDLow group was selected precisely for 
their lower verbal intelligence. There are some differences in adaptive behavior between these 
groups, particularly in the daily living skills domain. The communication domain is approaching 
significance, while the socialization domain is not significantly different. This is also consistent 
with our expectations, since the groups are separated by verbal IQ but not social deficits common 
to ASD. 
While the sample appears to have some unusual features related to the high IQ of the Typ 
group and age across groups, the tables above demonstrate that there are no significant 






IQ_Verbal 1 0.000101497 102.125 13.61800279 69.42857143 18.29259543
IQ_Nonverbal 1 0.00286087 106.5625 11.74716278 84 18.86796226
IQ_Spatial 1 0.003186254 97.9375 13.21851605 75.5 16.08415369
IQ_GCA 1 1.14746E-05 103.8 10.53700961 68.5 16.58613879
IQ_SNC 1 0.000937043 102.875 10.89877669 77.33333333 20.02664891
Vineland_Comm 0 0.073886234
Vineland_DLS 1 0.010714545 82.75 10.5229907 68.71428571 12.29788987
Vineland_Soc 0 0.589875197
Sex 0 0.113958894
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differences related to sex within the sample. Table 6 below provides a full analysis comparing 
psychological scores between males and females on every measure. While differences in IQ and 
age remain to be addressed as we continue our analysis, differences based on sex do not appear 
to be a factor in this sample. 
Table 6 
Summary of Sex Differences by Age and Assessment Scores 
 
Given the differences in age identified above, it is worthwhile to explore more deeply the 
relationship between age and psychological scores within this sample. Tables 7, 8 and 9 below 
present t-tests comparing three age groups within the sample, the youngest, middle and oldest 
thirds of subjects. Table 7 indicates that there is no significant difference between the youngest 
and middle third on any psychological measure collected in this sample. Table 8 indicates a 
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and table 9 indicates the same difference between the middle and oldest group. The differences 
on the ADOS Comparison scores arise due to the significantly higher older group average, 6.125, 
while the younger and middle group are 3.176 and 3.562 respectively. These differences help 
explain the correlations between age and ADOS scores seen in table 2. Tables 7, 8, and 9 also 
demonstrate that no significant differences are present between age groups in other domains 
assessed. 
Table 7 









Row T_test p_value Young_Mean Young_SD Med_Mean Med_SD
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Table 8 




Comparison Between the Middle and Oldest Third of the Sample by Age, Sex, and Assessment 
Scores 
 
Row T_test p_value Young_Mean Young_SD Old_Mean Old_SD














Row T_test p_value Med_Mean Med_SD Old_Mean Old_SD
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This initial analysis summarizes the psychological scores within our sample and 
compares these scores to demographic features of participants, namely age and sex. When 
looking at psychological scores within the sample, they are strongly correlated with one another. 
That means that higher performance in one domain is correlated with higher performance in 
other domains, while lower performance is one domain is correlated in lower performance in 
others. Age is not significantly correlated with any psychological score apart from ADOS-2 
comparison scores, and there are no significant differences based on sex. When we compare Typ, 
ASDAvg and ASDLow groups we find that, consistent with the correlational analysis, there are 
many significant differences across domains between groups. As a result of the groups being 
separated in part based on ADOS-2 comparison scores, age is significantly different between the 
Typ and ASDAvg group. The perturbation of age within the sample appears to stem from the 
unusually high ADOS-2 comparison scores among older participants. The second stage of our 
analysis involves comparing psychological scores and subject groups with sample entropy 
measurements. 
Sample Entropy Analysis 
 The sample entropy analysis proceeds in two parts. First, we explore the correlation 
between subjects’ psychological scores and sample entropy measurements. This analysis 
includes subtests of the ADOS-2, DAS-II and Vineland-II measurements, as well as age. Sample 
entropy is measured at 114 points for every participant, composed of six wavelength bands for 
each of 19 scalp locations. The second, and final phase of the analysis, proceeds by comparing 
the sample entropy between Typ, ASDAvg and ASDLow using ANOVA at each of the 114 
measurement points. 
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 Of the 114 sample entropy calculations available to provide a significant correlation with 
age or psychological scores, 25 measurements generated positive results. These are displayed 
below in Table 10, which has been divided in two for ease of reference. Fifteen of 19 scalp 
locations bore positive correlations with psychological scores, which are reported in the first row 
of Table 10. Wavelength bands are reported in the second row and suggest that specific bands 
are much more important for our analysis compared to others. The totals come to High Gamma 
(0), Gamma (1), Beta (1), Alpha (12), Theta (5), Delta (6). This suggests that sample entropy 
within the Alpha, Theta and Delta bands are most strongly correlated with the abilities, or 
symptoms, measured in the ADOS-2, DAS-II and Vineland-II. 
 The correlations presented in Table 10 are remarkably consistent in terms of direction of 
correlation across measures. Every significant correlation with ADOS-2 measures are negative, 
suggesting that higher levels of sample entropy are related to lower ADOS-2 scores and less 
symptomatology on this measure. Correlations with IQ and adaptive functioning are all positive, 
indicating that higher levels of sample entropy are related to higher performance in these 
domains. These results seem to suggest that higher levels of sample entropy in the locations and 
frequency bands identified below are indicative of better functioning across psychological 
domains and may help distinguish typical developing children and children diagnosed with ASD. 
Notably absent from the correlations presented in Table 10 are any positive relationships 
between sample entropy and verbal IQ, the measurement used to distinguish the ASDAvg and 
ASDLow groups. This may help explain the lack of differences detected between the ASDAvg 
and ASDLow discussed in Tables 11 – 16 below. Also important to note is the relative 
infrequency of correlations between age and sample entropy. Correlations with age are found in 
only 3 measurements, and in two of these age is the only attribute correlated within that 
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measurement. While age appeared to be an important factor in our initial analysis, demonstrated 
by its correlation with ADOS sores, it does not appear to be a significant factor in the sample 
entropy portion of our analysis. 
Table 10.1 
Summary of Correlations Between Entropy and Assessment Scores 
 
Tale 10.2 
Summary of Correlations Between Entropy and Assessment Scores 
 
 The ANOVA analysis proceeded in two steps. The first step involved comparing three 
groups – Typ, ASDAvg, ASDLow at each of the 114 sample entropy measures to see if there are 
Row C3_4 C4_4 F3_6 F4_6 F7_4 F7_6 F8_6 Fz_4 Fp1_4 Fp1_5 Fp2_4 Fp2_6
Frequency Scale Alpha Alpha Delta Delta Alpha Delta Delta Alpha Alpha Theta Alpha Delta
Age -0.293805573 0.353759846
ADOS_SA -0.384789229 -0.293874332 -0.282332101 -0.338235322
ADOS_RRB -0.315325566 -0.313480494
ADOS_Total -0.281710832 -0.393193148 -0.310930561 -0.281713274 -0.287863962






Vineland_Comm 0.300035292 0.364403366 0.282001807 0.299420835
Vineland_DLS 0.297647331
Vineland_Soc 0.297902926 0.285309293 0.307060005 0.317175071 0.295369341
Row P3_4 P3_5 P3_6 P4_2 P4_4 P4_5 Pz_3 Pz_4 Pz_5 T7_4 T7_5 P7_4 P8_4
Frequency Scale Alpha Theta Delta Gamma Alpha Theta Beta Alpha Theta Alpha Theta Alpha Alpha
Age -0.298849466
ADOS_SA -0.292377421 -0.290391313 -0.359160601 -0.314235224 -0.320895105 -0.302475922 -0.407844333 -0.36660881
ADOS_RRB -0.289692668 -0.341572741
ADOS_Total -0.312222506 -0.345983792 -0.346271695 -0.354166529 -0.296820316
ADOS_Comparison -0.350539837 -0.372218768 -0.308978085 -0.342987742 -0.398097401 -0.357284088
IQ_Verbal
IQ_Nonverbal
IQ_Spatial 0.303592445 0.320040613 0.307958542 0.321646005
IQ_GCA 0.296163955
IQ_SNC
Vineland_Comm 0.29969164 0.300701486 0.318490201 0.32121917 0.33302196
Vineland_DLS 0.299461493 0.295081067 0.341155895 0.353219201
Vineland_Soc 0.351154922 0.40897845 0.340980719
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any differences between groups. This analysis identified 10 sample entropy measurements with 
group differences. The second step involved comparing Typ, ASDAvg, ASDLow groups at each 
of the ten measurements to identify significant differences. Of the 10 groups originally 
identified, 6 had at least two groups that were significantly different. 
Table 11 
Entropy Comparison between Typically Developing Children, Children with ASD and Average 
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Table 12 
Entropy Comparison between Typically Developing Children, Children with ASD and Average 
Verbal Ability, and Children with ASD and Low Verbal Ability at the Fp2 Alpha Measurement. 
 
Table 13 
Entropy Comparison between Typically Developing Children, Children with ASD and Average 
Verbal Ability, and Children with ASD and Low Verbal Ability at the O2 Theta Measurement. 
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Table 14 
Entropy Comparison between Typically Developing Children, Children with ASD and Average 
Verbal Ability, and Children with ASD and Low Verbal Ability at the P4 Alpha Measurement. 
 
Table 15 
Entropy Comparison between Typically Developing Children, Children with ASD and Average 
Verbal Ability, and Children with ASD and Low Verbal Ability at the P4 Theta Measurement. 
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Table16 
Entropy Comparison between Typically Developing Children, Children with ASD and Average 
Verbal Ability, and Children with ASD and Low Verbal Ability at the Pz Alpha Measurement. 
 
These results are interpreted with greater detail in the discussion section, however, it is 
important to note a few important features. The first is that all groups belong to either the Alpha 
or Theta band. This reinforces the conception that group differences are strongest within these 
EEG frequency bands. Scalp locations are also consistent, with positive results primarily from 
the prefrontal cortex and parietal lobes. The group differences displayed in Table 13 are 
interesting for two reasons. First, the difference originates in the occipital lobe and there were no 
correlations between psychological scores and sample entropy in the occipital lobe, as displayed 
in Table 10. Second, Table 13 shows ASDAvg with lower sample entropy than both Typ and 
ASDLow groups. This is inconsistent with all other ANOVA measures, and the correlations in 
Table 10, which suggest that higher sample entropy is associated with typical development. The 
prefrontal cortex and parietal lobe also play a more central role in the cognitive processes which 
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tend to distinguish typically developing children and those diagnosed with ASD. Future studies 
will be needed to confirm the significance of the results presented in Table 13. 
Discussion 
 The sample used in this study appears representative of the broader population of 
children with ASD in terms of sex and cognitive ability. Sex was not correlated with ASD 
symptoms, adaptive functioning, or IQ, however, older children in the study appeared to have 
been diagnosed with ASD at a higher rate than younger children in the sample. This irregularity 
provides some challenges in interpreting our results and establishing the relationship between 
sample entropy and ASD symptomatology. 
 Sample entropy was correlated with behavioral measures at 25 of the 114 possible 
locations, with the majority occurring in Alpha, Theta, and Delta frequency bands. The ANOVA 
analysis differentiated groups within Alpha and Theta frequency bands. The consistency with 
which Alpha, Theta, and Delta frequencies generated positive results, in contrast with High 
Gamma, Gamma, and Beta frequencies, suggests that sample entropy as a marker for ASD in 
children is most significant within these frequency bands. 
 The direction of correlations was also consistent across our analysis. Higher levels of 
entropy were almost universally associated with lower ASD symptomatology and better adaptive 
functioning. Correlations in our analysis were moderate, ranging from .28 to .41 and were 
predominantly found within ADOS-2 and Vineland-II scores. Sample entropy was infrequently 
correlated with measures of intelligence and was never correlated with verbal IQ. 
 While all of the significant correlations in our study supported the conclusion that higher 
levels of sample entropy are associated with lower ASD symptoms and better adaptive 
functioning, one ANOVA result contradicted this trend. The results of the ANOVA for O2 Theta 
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indicate that sample entropy is significantly higher for the ASDAvg group when compared to 
both the Typ and ASDLow group. The limited number of participants in our study, along with 
the high number of analysis performed, suggest that this result may be an anomaly within our 
sample. Further research is needed to determine the veracity of this result, and determine if 
sample entropy at the O2 theta measurement is significantly different for children with ASD and 
average verbal ability. 
 Age was correlated with sample entropy in three instances, however, on two occasions it 
was the only significant correlation, and it did not have a consistent direction of correlation as 
found in behavioral measures. On two occasions lower sample entropy was correlated with 
higher age, and on one occasion higher sample entropy was correlated with higher age. None of 
the ANOVA analysis overlapped with significant age correlations. While future research may be 
interested in exploring the relationship between sample entropy and age, it would appear that the 
impact of the irregular relationship between age and ASD symptoms in our sample had little 
impact on the analysis produced. 
 The results of our study suggest that sample entropy is not a measure capable of 
identifying individuals with ASD and low verbal IQ. None of the six ANOVA measurements 
successfully distinguished ASDLow from both the ASDAvg and Typ groups. Additionally, 
sample entropy was not correlated with verbal IQ at any of 114 measurement points. While our 
sample was small, and the cutoff for the ASDLow group was a verbal IQ of 85, as opposed to the 
more common 70, researchers interested in identifying biomarkers of this subgroup may wish to 
devote resources to alternative avenues of inquiry. 
 Our study did not demonstrate a relationship between sample entropy and the low verbal 
subgroup of ASD, but it did demonstrate extensive and consistent correlations between sample 
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entropy and both ASD symptoms and adaptive behavior. Our results suggest that lower levels of 
sample entropy are correlated with higher levels of ASD symptoms and lower levels of adaptive 
functioning. The consistency of these results across a multitude of observations could also be 
interpreted as indicating that sample entropy is associated with a fundamental neurological 
process found in ASD.  
 In addition to the correlational analysis, our ANOVA analysis demonstrated that children 
diagnosed with ASD, of any verbal ability, can be distinguished from typically developing peers 
based upon measures of sample entropy. These results confirm and extend the findings in Bosl et 
al. (2011) which found that sample entropy could be used to distinguish infants and toddlers at 
high risk of ASD from typically developing counterparts. Our findings have shown that sample 
entropy may be used as a biomarker to identify ASD among older children, and also suggests 
that sample entropy may be an indication of underlying neurological processes implicated in 
ASD. The possibility that sample entropy is related to the etiology of ASD provides another line 
of inquiry for researchers interested in greater understanding of this disorder. 
 The results of our ANOVA analysis indicate that ASD and typically developing peers 
may be distinguished by sample entropy measurements in the prefrontal cortex and parietal lobe. 
Abnormal processing in the prefrontal cortex has been implicated in ASD, specifically related to 
core deficits in social cognition (Bicks, Koike, Akbarian, & Morishita, 2015; Paine, Swedlow, & 
Swetschinski, 2017). Research into the role that sample entropy may play in the etiology of ASD 
would benefit from replicating studies that use other methods to successfully identify 
abnormalities in the prefrontal cortex. This would solidify sample entropy as an additional 
measure to detect underlying neurological processes which contribute to ASD. 
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 Additional considerations for developing sample entropy as a useful measure of ASD 
involve demonstrating the reliability and stability of this measurement. Reliability of sample 
entropy measurements of EEG signals could be demonstrated by performing the same analysis 
on multiple EEG measurements taken at the same time, and over the course of several weeks or 
months. This would confirm that sample entropy is a reliable measurement of neurological 
process and allow for longitudinal studies to establish how stable sample entropy is over time. 
 The stability of sample entropy could be established through measurements taken over 
the course of years, and such studies would provide a baseline regarding the natural development 
of sample entropy over the course of an individual’s life. Regarding ASD, this baseline would 
allow for developmental trajectories of ASD, and typically developing peers which incorporate 
sample entropy measurements in order to understand how this metric may differ between groups. 
Incorporating sample entropy into these studies could also explore how sample entropy changes 
in the course of behavioral treatment for ASD. 
 Our study has several limitations. First, our sample size of 49 was relatively small, and 
conclusions drawn from our results are necessarily conservative. Further studies are needed to 
verify the veracity of our findings. Second, our secondary data analysis precluded a better 
understanding of participant demographics and treatment history. This limited the scope of our 
initial analysis which provided a better understanding of the composition of our sample.  
Despite these limitations, it appears that sample entropy may be a reliable measure of 
autistic symptomatology for children between 4 and 11 years of age. These results confirm and 
extend earlier applications of sample entropy to distinguish children at high risk of ASD from 
typically developing counterparts (Bosl et al., 2011). Our results suggest that further research 
into sample entropy is warranted to develop this measure into a viable aspect of future studies on 
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ASD, particularly longitudinal studies attempting to identify developmental trajectories of 
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Manually import original data file-by-file using Matlab 
import function. This auto-formats table contents. 
Contents 
 Save imported data 
 Load Data 
 Implement CleanTables Function 
 Add Column to Identify Module/Version 
 Determine Dx, Language Level and combined 
 This Section has been commented-out because we are not using these features in this analysis 
 Select Total Scores 
 Rename Total Score Columns for DAS and ADOS, which allows for concatenation 
 Concatenate Versions of ADOS and DAS 
 Remove Duplicate Rows 
 Manually remove rows from Table flagged above 
 Join Tables 
 Determine Final Categories 
 Save Table 
 End 









ADI = readtable('adi.xlsx'); 
ADOSm1 = readtable('adosm1.xlsx'); 
ADOSm2 = readtable('adosm2.xlsx'); 
ADOSm3 = readtable('adosm3.xlsx'); 
DASEY = readtable('dasey.xlsx'); 
DASSA = readtable('dassa.xlsx'); 
Vineland = readtable('vineland.xlsx'); 
EEG_Analysis = readtable('NDAR_data_SE_RQA.xlsx'); 
Implement CleanTables Function 
This deletes redundant column headers and standardizes missing values. 
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ADI = CleanTables(ADI); 
ADOSm1 = CleanTables(ADOSm1); 
ADOSm2 = CleanTables(ADOSm2); 
ADOSm3 = CleanTables(ADOSm3); 
DASEY = CleanTables(DASEY); 
DASSA = CleanTables(DASSA); 
Vineland = CleanTables(Vineland); 
Add Column to Identify Module/Version 
ADOSm1.Module(:, 1) = 1; 
ADOSm2.Module(:, 1) = 2; 
ADOSm3.Module(:, 1) = 3; 
DASEY.Version(:,1) = "EY"; 
DASSA.Version(:,1) = "SA"; 
Determine Dx, Language Level and combined 
%ADOS Module 1 Dx 
for i = 1:height(ADOSm1) 
    if ADOSm1.scoresumm_compscore(i) >= 4 
        ADOSm1.Autism_Dx(i) = 1; 
    else 
        ADOSm1.Autism_Dx(i) = 0; 
    end 
end 
%ADOS Module 2 Dx 
for i = 1:height(ADOSm2) 
    if ADOSm2.scoresumm_compscore(i) >= 4 
        ADOSm2.Autism_Dx(i) = 1; 
    else 
        ADOSm2.Autism_Dx(i) = 0; 
    end 
end 
%ADOS Module 3 Dx 
for i = 1:height(ADOSm3) 
    if ADOSm3.scoresumm_compscore(i) >= 4 
        ADOSm3.Autism_Dx(i) = 1; 
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    else 
        ADOSm3.Autism_Dx(i) = 0; 
    end 
end 
%DAS EY Low IQ 
for i = 1:height(DASEY) 
    if DASEY.dasii_eyr_verbal_ss(i) < 85 
        DASEY.Low_Verbal(i) = 1; 
    else 
        DASEY.Low_Verbal(i) = 0; 
    end 
end 
%DAS SA Low IQ 
for i = 1:height(DASSA) 
    if DASSA.dasii_sar_verbal_ss(i) < 85 
        DASSA.Low_Verbal(i) = 1; 
    else 
        DASSA.Low_Verbal(i) = 0; 
    end 
end 
This Section has been commented-out because we are not using 
these features in this analysis 
%ADI Minimally Verbal for i = 1:height(ADI) if ADI.funccom_levell(i) == 2 ADI.Minimally_Verbal(i) = 1; else 
ADI.Minimally_Verbal(i) = 0; end end %DAS SA Poor Expressive Language for i = 1:height(DASSA) if 
ismissing(DASSA.dasii_sar_wdef_tscr(i)) DASSA.DAS_Poor_Expressive(i) = NaN; elseif 
DASSA.dasii_sar_wdef_tscr(i) >=10 && DASSA.dasii_sar_wdef_tscr(i) <= 49 DASSA.DAS_Poor_Expressive(i) = 1; 
else DASSA.DAS_Poor_Expressive(i) = 0; end end x = nan(height(DASEY)); % Initialize NaN matrix to add to 
DASEY DASEY.DAS_Poor_Expressive = x; % Add column to DASEY to be consistent with DASSA %DAS SA Poor 
Expressive Semantics for i = 1:height(DASSA) if ismissing(DASSA.dasii_sar_vsim_tscr(i)) 
DASSA.DAS_Poor_Expressive(i) = NaN; elseif DASSA.dasii_sar_vsim_tscr(i) >=10 && 
DASSA.dasii_sar_wdef_tscr(i) <= 50 DASSA.DAS_Poor_Expressive_Semantics(i) = 1; else 
DASSA.DAS_Poor_Expressive_Semantics(i) = 0; end end DASEY.DAS_Poor_Expressive_Semantics = x; %Adds 
column to DASEY to be consistent with DASSA 
Select Total Scores 
GUIDs and total scores with inerpretations for all - ADOS includes age and sex 
ADI_Total = ADI(:, {'subjectkey', 'dbaes_atotal', 'dbaes_ctotal', 'dbaes_dtotal'}); 
ADOSm1_Total = ADOSm1(:, {'subjectkey', 'interview_age', 'gender', 
'scoresumm2_abtotal', 'scoresumm_adtotal', ... 
    'scoresumm_overalltotal', 'scoresumm_compscore', 'Module', 'Autism_Dx'}); 
ADOSm2_Total = ADOSm2(:, {'subjectkey', 'interview_age', 'gender', 
'scoresumm2_abtotal', 'scoresumm_adtotal', ... 
    'scoresumm_overalltotal', 'scoresumm_compscore', 'Module', 'Autism_Dx'}); 
ADOSm3_Total = ADOSm3(:, {'subjectkey', 'interview_age', 'gender', 
'scoresumm2_abtotal', 'scoresumm_adtotal', ... 
ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD  63 
 
    'scoresumm_overalltotal', 'scoresumm_compscore', 'Module', 'Autism_Dx'}); 
DASEY_Total = DASEY(:, {'subjectkey', 'dasii_eyr_verbal_ss','dasii_eyr_nonverb_r_ss', 
'dasii_eyr_spatial_ss', ... 
    'dasii_eyr_gca_ss', 'dasii_eyr_snc_ss', 'Version', 'Low_Verbal'}); 
DASSA_Total = DASSA(:, {'subjectkey', 'dasii_sar_verbal_ss','dasii_sar_nvr_ss', 
'dasii_sar_spatial_ss', ... 
    'dasii_sar_gca_ss', 'dasii_sar_snc_ss', 'Version', 'Low_Verbal'}); 
Vineland_Total = Vineland(:, {'subjectkey', 'communicationdomain_total', 
'livingskillsdomain_total', ... 
    'socializationdomain_total'}); 
Rename Total Score Columns for DAS and ADOS, which allows for 
concatenation 
DASEY_Total.Properties.VariableNames{'dasii_eyr_verbal_ss'} = 'Verbal'; 
DASEY_Total.Properties.VariableNames{'dasii_eyr_nonverb_r_ss'} = 'Nonverbal'; 
DASEY_Total.Properties.VariableNames{'dasii_eyr_spatial_ss'} = 'Spatial'; 
DASEY_Total.Properties.VariableNames{'dasii_eyr_gca_ss'} = 'GCA'; 
DASEY_Total.Properties.VariableNames{'dasii_eyr_snc_ss'} = 'SNC'; 
DASSA_Total.Properties.VariableNames{'dasii_sar_verbal_ss'} = 'Verbal'; 
DASSA_Total.Properties.VariableNames{'dasii_sar_nvr_ss'} = 'Nonverbal'; 
DASSA_Total.Properties.VariableNames{'dasii_sar_spatial_ss'} = 'Spatial'; 
DASSA_Total.Properties.VariableNames{'dasii_sar_gca_ss'} = 'GCA'; 
DASSA_Total.Properties.VariableNames{'dasii_sar_snc_ss'} = 'SNC'; 
Concatenate Versions of ADOS and DAS 
ADOS_Total = vertcat(ADOSm1_Total, ADOSm2_Total, ADOSm3_Total); 
DAS_Total = vertcat(DASEY_Total, DASSA_Total); 
Remove Duplicate Rows 
ADI_Total = RemoveDuplicateRows(ADI_Total); 
ADOS_Total = RemoveDuplicateRows(ADOS_Total); 
DAS_Total = RemoveDuplicateRows(DAS_Total); 
Vineland_Total = RemoveDuplicateRows(Vineland_Total); 
Manually remove rows from Table flagged above 
NDARP351LEP 
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DAS_Total.Verbal(12) = 80;                  % Participant had verbal score from EY and 
remaining scores from SA 
DAS_Total.Version(12) = 'EY&SA'; 
DAS_Total.Low_Verbal(12) = DAS_Total.Low_Verbal(11); % Transfer Low_Verbal Category 
with Vebal Score 
DAS_Total = DAS_Total([1:10 12:end], :); 
% NDARRC664GBF 
DAS_Total = DAS_Total([1:27 29:end], :);    % Participant had EY scores but no SA 
scores 
% NDARTW441YZ7 
DAS_Total.Verbal(31) = 87;                  % Participant had much higher verbal score 
from EY. I used this score and ... 
DAS_Total.GCA(31) = NaN;                    % kept others from SA, setting GCA to NaN. 
Also changed low verbal. 
DAS_Total.Version(31) = 'EY&SA'; 
DAS_Total.Low_Verbal(31) = DAS_Total.Low_Verbal(32); % Transfer Low_Verbal Category 
with Vebal Score 
DAS_Total = DAS_Total([1:31 33:end], :); 
DAS_Total = RemoveDuplicateRows(DAS_Total); % Check for duplicate row warning 
Join Tables 
Total = outerjoin(ADOS_Total, ADI_Total, 'MergeKeys', true); 
Total = outerjoin(Total, DAS_Total, 'MergeKeys', true); 
Total = outerjoin(Total, Vineland_Total, 'MergeKeys', true); 
Total = innerjoin(Total, EEG_Analysis); 
Determine Final Categories 
for i = 1:size(Total,1) 
    if Total.Autism_Dx(i) == 0 && Total.Low_Verbal(i) == 0 
        Total.Final_Cats(i) = 0; 
    elseif Total.Autism_Dx(i) == 1 && Total.Low_Verbal(i) == 0 
        Total.Final_Cats(i) = 1; 
    elseif Total.Autism_Dx(i) == 1 && Total.Low_Verbal(i) == 1 
        Total.Final_Cats(i) = 2; 
    elseif Total.Autism_Dx(i) == 0 && Total.Low_Verbal(i) == 1 
        Total.Final_Cats(i) = 4; 
    else 
        Total.Final_Cats(i) = NaN; 
    end 
end 
%Reorder with Final_Cats at end of scores 
Total = Total(:, [1:22, end, 23:end-1]); 
Save Table 
writetable(Total, 'ScoresAndEEG.xlsx'); 
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End 
Convert to Matrices 
Contents 
 Load ScoresAndEEG 
 Separate Demographic Information and Scores 
 Convert Scores to Matrices 
 Convert EEG to Matrices 
 Clear unneeded variables 
 Save wokspace variables 
Load ScoresAndEEG 
ScoresAndEEG = readtable('ScoresAndEEG.xlsx'); 
Separate Demographic Information and Scores 
GUID = ScoresAndEEG(:,{'subjectkey'}); 
Age = ScoresAndEEG(:,{'interview_age'}); 
Sex = ScoresAndEEG(:,{'gender'}); 
Diagnosis = ScoresAndEEG(:,{'Autism_Dx'}); 
ADOS_Module = ScoresAndEEG(:,{'Module'}); 
Low_Verbal = ScoresAndEEG(:,{'Low_Verbal'}); 
DAS_Version = ScoresAndEEG(:,{'Version'}); 
ADOS = ScoresAndEEG(:,{'scoresumm2_abtotal', 'scoresumm_adtotal', 
'scoresumm_overalltotal', 'scoresumm_compscore'}); 
ADI = ScoresAndEEG(:,{'dbaes_atotal', 'dbaes_ctotal', 'dbaes_dtotal'}); 
IQ = ScoresAndEEG(:,{'Verbal', 'Nonverbal', 'Spatial', 'GCA', 'SNC'}); 
Vineland = ScoresAndEEG(:,{'communicationdomain_total', 'livingskillsdomain_total', 
'socializationdomain_total'}); 
Final_Cats = ScoresAndEEG(:,{'Final_Cats'}); 
Convert Scores to Matrices 
GUID = table2array(GUID);                               % NDAR Identifiers 
Age = table2array(Age);                                 % In months, at time of ADOS 
Sex = categorical(table2array(Sex));                    % M/F as categorical 
Diagnosis = categorical(table2array(Diagnosis));        % Dx as categorical 
ADOS_Module = categorical(table2array(ADOS_Module));    % ADOS Module as categorical 
Low_Verbal = categorical(table2array(Low_Verbal));      % Low verbal IQ as categorical 
DAS_Version = categorical(table2array(DAS_Version));    % DAS Version as categorical 
ADOS = table2array(ADOS);                               % SA, RRB, Total, Comparison, 
Module 
ADI = table2array(ADI);                                 % Sections A, C, D 
IQ = table2array(IQ);                                   % Verbal, Nonverbal, Spatial, 
GCA, SNC, DAS Version 
Vineland = table2array(Vineland);                       % Communication, Daily Living 
Skills, Socialization 
ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD  66 
 
Final_Cats = categorical(table2array(Final_Cats));      % All combinations of ASD(+,-) 
and Low Verbal(+,-) as categorical 
Convert EEG to Matrices 
x = find(strcmpi(ScoresAndEEG.Properties.VariableNames,'SampE_C3_cD1')); % Find the 
column number that begins EEG records 
SampE = ScoresAndEEG(:, x: x+113); 
SampE2D = table2array(SampE); 
SampE3D = SortEEG(SampE2D); 
SampE_VariableNames = ScoresAndEEG.Properties.VariableNames(x:x+113); 




Save workspace variables 
save('Variables.mat'); 
END 
Result of Basic Psych Statistics 
Contents 
 Load Variables 
 Subgroup Indexing 
 Run BasicStats on Complete Sample 
 Run BasicStats on TypAvgV 
 Run BasicStats on ASDAvgV 
 Run BasicStats on ASDLowV 






TypAvgV = find(Final_Cats == '0'); 
ASDAvgV = find(Final_Cats == '1'); 
ASDLowV = find(Final_Cats == '2'); 
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List_Full = {'Age', 'ADOS_SA', 'ADOS_RRB', 'ADOS_Total', 'ADOS_Comparison', 'ADI_A', 
'ADI_C', 'ADI_D', 'IQ_Verbal', 'IQ_Nonverbal', ... 
    'IQ_Spatial', 'IQ_GCA', 'IQ_SNC', 'Vineland_Comm', 'Vineland_DLS', 
'Vineland_Soc'}; 
Run BasicStats on Complete Sample 
a = BasicStats(Age); 
b = BasicStats(ADOS); 
c = BasicStats(ADI); 
d = BasicStats(IQ); 
e = BasicStats(Vineland); 
 
Total_Psych_Stats = vertcat(a, b, c, d, e); 
Total_Psych_Stats = array2table(Total_Psych_Stats); 
Total_Psych_Stats.Properties.VariableNames = {'Min', 'Max', 'Mean', 
'Standard_Deviation'}; 
Total_Psych_Stats.Properties.RowNames = List_Full; 
Run BasicStats on TypAvgV 
a = BasicStats(Age(TypAvgV, :)); 
b = BasicStats(ADOS(TypAvgV, :)); 
c = BasicStats(ADI(TypAvgV, :)); 
d = BasicStats(IQ(TypAvgV, :)); 
e = BasicStats(Vineland(TypAvgV, :)); 
 
TypAvgV_Psych_Stats = vertcat(a, b, c, d, e); 
TypAvgV_Psych_Stats = array2table(TypAvgV_Psych_Stats); 
TypAvgV_Psych_Stats.Properties.VariableNames = {'Min', 'Max', 'Mean', 
'Standard_Deviation'}; 
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TypAvgV_Psych_Stats.Properties.RowNames = List_Full; 
Run BasicStats on ASDAvgV 
a = BasicStats(Age(ASDAvgV, :)); 
b = BasicStats(ADOS(ASDAvgV, :)); 
c = BasicStats(ADI(ASDAvgV, :)); 
d = BasicStats(IQ(ASDAvgV, :)); 
e = BasicStats(Vineland(ASDAvgV, :)); 
 
ASDAvgV_Psych_Stats = vertcat(a, b, c, d, e); 
ASDAvgV_Psych_Stats = array2table(ASDAvgV_Psych_Stats); 
ASDAvgV_Psych_Stats.Properties.VariableNames = {'Min', 'Max', 'Mean', 
'Standard_Deviation'}; 
ASDAvgV_Psych_Stats.Properties.RowNames = List_Full; 
Run BasicStats on ASDLowV 
a = BasicStats(Age(ASDLowV, :)); 
b = BasicStats(ADOS(ASDLowV, :)); 
c = BasicStats(ADI(ASDLowV, :)); 
d = BasicStats(IQ(ASDLowV, :)); 
e = BasicStats(Vineland(ASDLowV, :)); 
 
ASDLowV_Psych_Stats = vertcat(a, b, c, d, e); 
ASDLowV_Psych_Stats = array2table(ASDLowV_Psych_Stats); 
ASDLowV_Psych_Stats.Properties.VariableNames = {'Min', 'Max', 'Mean', 
'Standard_Deviation'}; 
ASDLowV_Psych_Stats.Properties.RowNames = List_Full; 
Write results as table 
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writetable(Total_Psych_Stats, 'Basic_Psych_Stats.xlsx', 'sheet', 'Full_Sample', 
'WriteRowNames', true) 
writetable(TypAvgV_Psych_Stats, 'Basic_Psych_Stats.xlsx', 'sheet', 
'Typical_Avgerage_Verbal', 'WriteRowNames', true) 
writetable(ASDAvgV_Psych_Stats, 'Basic_Psych_Stats.xlsx', 'sheet', 
'ASD_Avgerage_Verbal', 'WriteRowNames', true) 
writetable(ASDLowV_Psych_Stats, 'Basic_Psych_Stats.xlsx', 'sheet', 'ASD_Low_Verbal', 
'WriteRowNames', true) 
Error using writetable (line 124) 
Unable to write to file 'Basic_Psych_Stats.xlsx'.  Ensure the file is a valid 
spreadsheet file and is not password protected. 
 
Error in Results_of_Basic_Psych_Statistics (line 56) 
writetable(Total_Psych_Stats, 'Basic_Psych_Stats.xlsx', 'sheet', 'Full_Sample', 
'WriteRowNames', true) 
End 
Results of Sex T-tests 
Contents 
 Load Variables 
 Subgroup indexing by sex used in function SexTtest 
 Sex Ttest 





Subgroup indexing by sex used in function SexTtest 
Malei = find(Sex == 'M');           % Male 
Femalei = find(Sex == 'F');         % Female 
List_Full = {'Age', 'Sex' 'ADOS_SA', 'ADOS_RRB', 'ADOS_Total', 'ADOS_Comparison', 
'Diagnosis', 'ADI_A', 'ADI_C', 'ADI_D', 'IQ_Verbal', 'IQ_Nonverbal', ... 
    'IQ_Spatial', 'IQ_GCA', 'IQ_SNC', ' Low_Verbal', 'Vineland_Comm', 'Vineland_DLS', 
'Vineland_Soc', 'Final_Cats'}; 
Sex Ttest 
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[Ttest, pvalue, ci, stats] = SexTtest(Age);                                          % 
Run Age T-test 
AgeSexTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];        % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = SexTtest(Sex);                                          % 
Run Sex T-test 
SexSexTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];        % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = SexTtest(ADOS);                                         % 
Run ADOS T-test 
ADOSSexTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];        % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = SexTtest(Diagnosis);                                    % 
Run Diagnosis T-test 
DiagnosisSexTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];  % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = SexTtest(ADI);                                          % 
Run ADI T-test 
ADISexTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];         % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = SexTtest(IQ);                                           % 
Run IQ T-test 
IQSexTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];          % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = SexTtest(Low_Verbal);                                   % 
Run Low_Verbal T-test 
Low_VerbalSexTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = SexTtest(Vineland);                                     % 
Run Vineland T-test 
VinelandSexTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];    % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = SexTtest(Final_Cats);                                   % 
Run Sex T-test 
Final_CatsSexTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; % 
Concatenate Results 
 
Sex_Ttest_Full = vertcat(AgeSexTtestResults, SexSexTtestResults, ADOSSexTtestResults, 
DiagnosisSexTtestResults, ADISexTtestResults, ... 
    IQSexTtestResults, Low_VerbalSexTtestResults, VinelandSexTtestResults, 
Final_CatsSexTtestResults);    % Verically Concatenate all results 
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Sex_Ttest_Full = array2table(Sex_Ttest_Full);                                                           
% Convert to table 
Sex_Ttest_Full.Properties.VariableNames = {'T_test', 'p_value', 'ci_low', 'ci_high', 
... 
    'value_of_test_statistic', 'degrees_of_freedom', 'standard_deviation'};                           
% Label Columns 
Sex_Ttest_Full.Properties.RowNames = List_Full; 
Write Results as Table 
writetable(Sex_Ttest_Full, 'Sex_Ttest.xlsx', 'WriteRowNames', true) 
End 
Results of Age T-tests 
Contents 
 Load Variables 
 Subgroup Indexing by age used in functions below 
 Young Med T-Tests 
 Young Old T-Tests 
 Med Old T-Tests 





Subgroup Indexing by age used in functions below 
Youngi = find(Age<74);              % Bottom 3rd 
Medi = find(Age>=74 & Age<105);     % Middle 3rd 
Oldi = find(Age>=105);              % Top 3rd 
List_Full = {'Age', 'Sex', 'ADOS_SA', 'ADOS_RRB', 'ADOS_Total', 'ADOS_Comparison', 
'Diagnosis', 'ADI_A', 'ADI_C', 'ADI_D', 'IQ_Verbal', 'IQ_Nonverbal', ... 
    'IQ_Spatial', 'IQ_GCA', 'IQ_SNC', ' Low_Verbal', 'Vineland_Comm', 'Vineland_DLS', 
'Vineland_Soc', 'Final_Cats'}; 
Young Med T-Tests 
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Age);                                          
% Run Age T-test 
AgeYMTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];        % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Sex);                                  % 
Run Sex T-test 
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SexYMTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];        % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(ADOS);                                 % 
Run ADOS T-test 
ADOSYMTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];        % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Diagnosis);                            % 
Run Diagnosis T-test 
DiagnosisYMTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];  % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(ADI);                                  % 
Run ADI T-test 
ADIYMTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];         % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(IQ);                                   % 
Run IQ T-test 
IQYMTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];          % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Low_Verbal);                           % 
Run Low_Verbal T-test 
Low_VerbalYMTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Vineland);                             % 
Run Vineland T-test 
VinelandYMTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];    % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Young_Med_Ttest(Final_Cats);                           % 
Run Sex T-test 
Final_CatsYMTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; % 
Concatenate Results 
 
YM_Ttest_Full = vertcat(AgeYMTtestResults, SexYMTtestResults, ADOSYMTtestResults, 
DiagnosisYMTtestResults, ADIYMTtestResults, ... 
    IQYMTtestResults, Low_VerbalYMTtestResults, VinelandYMTtestResults, 
Final_CatsYMTtestResults);    % Verically Concatenate all results 
YM_Ttest_Full = array2table(YM_Ttest_Full);                                                           
% Convert to table 
YM_Ttest_Full.Properties.VariableNames = {'T_test', 'p_value', 'ci_low', 'ci_high', 
... 
    'value_of_test_statistic', 'degrees_of_freedom', 'standard_deviation'};                           
% Label Columns 
YM_Ttest_Full.Properties.RowNames = List_Full; 
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Young Old T-Tests 
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Age);                                          
% Run Age T-test 
AgeYOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];        % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Sex);                                  % 
Run Sex T-test 
SexYOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];        % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(ADOS);                                 % 
Run ADOS T-test 
ADOSYOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];        % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Diagnosis);                            % 
Run Diagnosis T-test 
DiagnosisYOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];  % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(ADI);                                  % 
Run ADI T-test 
ADIYOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];         % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(IQ);                                   % 
Run IQ T-test 
IQYOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];          % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Low_Verbal);                           % 
Run Low_Verbal T-test 
Low_VerbalYOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Vineland);                             % 
Run Vineland T-test 
VinelandYOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];    % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Young_Old_Ttest(Final_Cats);                           % 
Run Sex T-test 
Final_CatsYOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; % 
Concatenate Results 
 
YO_Ttest_Full = vertcat(AgeYOTtestResults, SexYOTtestResults, ADOSYOTtestResults, 
DiagnosisYOTtestResults, ADIYOTtestResults, ... 
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    IQYOTtestResults, Low_VerbalYOTtestResults, VinelandYOTtestResults, 
Final_CatsYOTtestResults);    % Verically Concatenate all results 
YO_Ttest_Full = array2table(YO_Ttest_Full);                                                           
% Convert to table 
YO_Ttest_Full.Properties.VariableNames = {'T_test', 'p_value', 'ci_low', 'ci_high', 
... 
    'value_of_test_statistic', 'degrees_of_freedom', 'standard_deviation'};                           
% Label Columns 
YO_Ttest_Full.Properties.RowNames = List_Full; 
Med Old T-Tests 
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Age);                                          
% Run Age T-test 
AgeMOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];        % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Sex);                                    % 
Run Sex T-test 
SexMOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];        % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(ADOS);                                   % 
Run ADOS T-test 
ADOSMOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];        % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Diagnosis);                              % 
Run Diagnosis T-test 
DiagnosisMOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd'];  % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(ADI);                                    % 
Run ADI T-test 
ADIMOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];         % 
Concatenate Results 
 
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(IQ);                                     % 
Run IQ T-test 
IQMOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];          % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Low_Verbal);                             % 
Run Low_Verbal T-test 
Low_VerbalMOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Vineland);                               % 
Run Vineland T-test 
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VinelandMOTtestResults = [Ttest, pvalue, ci, stats.tstat',stats.df', stats.sd'];    % 
Concatenate results 
 
[Ttest, pvalue, ci, stats] = Med_Old_Ttest(Final_Cats);                             % 
Run Sex T-test 
Final_CatsMOTtestResults = [Ttest, pvalue, ci, stats.tstat', stats.df', stats.sd']; % 
Concatenate Results 
 
MO_Ttest_Full = vertcat(AgeMOTtestResults, SexMOTtestResults, ADOSMOTtestResults, 
DiagnosisMOTtestResults, ADIMOTtestResults, ... 
    IQMOTtestResults, Low_VerbalMOTtestResults, VinelandMOTtestResults, 
Final_CatsMOTtestResults);    % Verically Concatenate all results 
MO_Ttest_Full = array2table(MO_Ttest_Full);                                                           
% Convert to table 
MO_Ttest_Full.Properties.VariableNames = {'T_test', 'p_value', 'ci_low', 'ci_high', 
... 
    'value_of_test_statistic', 'degrees_of_freedom', 'standard_deviation'};                           
% Label Columns 
MO_Ttest_Full.Properties.RowNames = List_Full; 
Write Results as Tables 
writetable(YM_Ttest_Full, 'Age_Ttest.xlsx', 'sheet', 'Young_Medium', 'WriteRowNames', 
true) 
writetable(YO_Ttest_Full, 'Age_Ttest.xlsx', 'sheet', 'Young_Old', 'WriteRowNames', 
true) 
writetable(MO_Ttest_Full, 'Age_Ttest.xlsx', 'sheet', 'Medium_Old', 'WriteRowNames', 
true) 
End 
Results of Psych Correlations 
Contents 
 Load Variables 
 Run Correlation Between all Psych Scores 
 Isolate Statistically Significant Correlations 
 Convert to tables and only show correlations once - in upper half of tiangle 





List_Full = {'ADOS_SA', 'ADOS_RRB', 'ADOS_Total', 'ADOS_Comparison', 'ADI_A', 'ADI_C', 
'ADI_D', 'IQ_Verbal', 'IQ_Nonverbal', ... 
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    'IQ_Spatial', 'IQ_GCA', 'IQ_SNC', 'Vineland_Comm', 'Vineland_DLS', 'Vineland_Soc', 
'Age'}; 
Run Correlation Between all Psych Scores 
Don't change order of analysis, it is tied to the Psych_Correlation Function 
[ADOSco, ADOSp] = Psych_Correlation(ADOS); 
[ADIco, ADIp] = Psych_Correlation(ADI); 
[IQco, IQp] = Psych_Correlation(IQ); 
[Vinelandco, Vinelandp] = Psych_Correlation(Vineland); 
[Ageco, Agep] = Psych_Correlation(Age); 
 
% Concatenate all correlations and all p-values into two separate matrices 
Correlations = vertcat(ADOSco, ADIco, IQco, Vinelandco, Ageco); 
p_Values = vertcat(ADOSp, ADIp, IQp, Vinelandp, Agep); 
Isolate Statistically Significant Correlations 
keep correlations with p-values less than .05 and replace all correlations and p-values with NaN 
Sig_p_Values = p_Values; 
Sig_Correlations = Correlations; 
for i = 1:size(Correlations, 1) 
    for j = 1:size(Correlations, 2) 
        if Sig_p_Values(i,j)> .05 
            Sig_p_Values(i,j) = (NaN); 
            Sig_Correlations(i,j) = (NaN); 
        end 
    end 
end 
Convert to tables and only show correlations once - in upper half of 
tiangle 
Sig_Correlations = triu(Sig_Correlations);                  % Correlation and p-Values 
displayed twice in square, this isolates upper half 
Sig_p_Values = triu(Sig_p_Values); 
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Sig_Correlations = array2table(Sig_Correlations);           % Convert to table 
Sig_p_Values = array2table(Sig_p_Values); 
 
Sig_Correlations.Properties.VariableNames = List_Full;      % Add column and row names 
Sig_Correlations.Properties.RowNames = List_Full; 
 
Sig_p_Values.Properties.VariableNames = List_Full;          % Add column and row names 
Sig_p_Values.Properties.RowNames = List_Full; 
Write Table to File 
writetable(Sig_Correlations,'Psych_Correlations.xlsx', 'sheet', 'Correlations', 
'WriteRowNames', true); 
writetable(Sig_p_Values,'Psych_Correlations.xlsx', 'sheet', 'p_values', 
'WriteRowNames', true); 
End 
Sample Entropy and Psych Scores Correlation 
Contents 
 Load Variables 
 Correlations Psych Scores and SampE 
 Only Significant 
 Add Frequency Scale to First Row 
 Create Tables 
 Condense Columns to EEG Scalp Locations 





List_Full = {'Frequency Scale' 'Age', 'ADOS_SA', 'ADOS_RRB', 'ADOS_Total', 
'ADOS_Comparison', 'ADI_A', 'ADI_C', 'ADI_D', 'IQ_Verbal', 'IQ_Nonverbal', ... 
    'IQ_Spatial', 'IQ_GCA', 'IQ_SNC', 'Vineland_Comm', 'Vineland_DLS', 
'Vineland_Soc'}; 
Correlations Psych Scores and SampE 
[Ageco, Agep] = corr(Age, SampE2D, 'rows', 'complete'); 
[ADOSco, ADOSp] = corr(ADOS, SampE2D, 'rows', 'complete'); 
[ADIco, ADIp] = corr(ADI, SampE2D,'rows', 'complete'); 
[IQco, IQp] = corr(IQ, SampE2D, 'rows', 'complete'); 
[Vinelandco, Vinelandp] = corr(Vineland, SampE2D, 'rows', 'complete'); 
 
FullCorrelation = vertcat(Ageco, ADOSco, ADIco, IQco, Vinelandco); 
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FullP = vertcat(Ageco, ADOSp, ADIp, IQp, Vinelandp); 
Only Significant 
for i = 1:size(FullP,1) 
    for j = 1:size(FullP,2) 
        if FullP(i,j)> .05 
            FullP(i,j) = NaN; 
            FullCorrelation(i,j) = NaN; 
        end 
    end 
end 
Add Frequency Scale to First Row 
FullCorrelation(2:17,:) = FullCorrelation(1:16,:); 
FullP(2:17,:) = FullP(1:16,:); 
for i = 1:6 
    if i == 1 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "High Gamma"; 
    elseif i == 2 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Gamma"; 
    elseif i == 3 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Beta"; 
    elseif i == 4 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Alpha"; 
    elseif i == 5 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Theta"; 
    elseif i == 6 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Delta"; 
    end 
end 
FullCorrelation = num2cell(FullCorrelation); 
FullP = num2cell(FullP); 
for i = 1:114 
    FullCorrelation{1,i} = zz{1,i}; 
    FullP{1,i} = zz{1,i}; 
end 
Create Tables 
convert correlation coeficients to Table 
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FullCorrelation = array2table(FullCorrelation); 
FullCorrelation.Properties.VariableNames = SampE_VariableNames; 
FullCorrelation.Properties.RowNames = List_Full; 
 
FullP = array2table(FullP); 
FullP.Properties.VariableNames = SampE_VariableNames; 
FullP.Properties.RowNames = List_Full; 
Condense Columns to EEG Scalp Locations 
write new columns 
FullCorrelation.C3 = FullCorrelation{:,1:6}; 
FullCorrelation.C4 = FullCorrelation{:,7:12}; 
FullCorrelation.O1 = FullCorrelation{:,13:18}; 
FullCorrelation.O2 = FullCorrelation{:,19:24}; 
FullCorrelation.Cz = FullCorrelation{:,25:30}; 
FullCorrelation.F3 = FullCorrelation{:,31:36}; 
FullCorrelation.F4 = FullCorrelation{:,37:42}; 
FullCorrelation.F7 = FullCorrelation{:,43:48}; 
FullCorrelation.F8 = FullCorrelation{:,49:54}; 
FullCorrelation.Fz = FullCorrelation{:,55:60}; 
FullCorrelation.Fp1 = FullCorrelation{:,61:66}; 
FullCorrelation.Fp2 = FullCorrelation{:,67:72}; 
FullCorrelation.P3 = FullCorrelation{:,73:78}; 
FullCorrelation.P4 = FullCorrelation{:,79:84}; 
ENTROPY AS A METHOD FOR IDENTIFYING TREATMENT RESISTANT ASD  80 
 
FullCorrelation.Pz = FullCorrelation{:,85:90}; 
FullCorrelation.T7 = FullCorrelation{:,91:96}; 
FullCorrelation.T8 = FullCorrelation{:,97:102}; 
FullCorrelation.P7 = FullCorrelation{:,103:108}; 
FullCorrelation.P8 = FullCorrelation{:,109:114}; 
 
FullP.C3 = FullP{:,1:6}; 
FullP.C4 = FullP{:,7:12}; 
FullP.O1 = FullP{:,13:18}; 
FullP.O2 = FullP{:,19:24}; 
FullP.Cz = FullP{:,25:30}; 
FullP.F3 = FullP{:,31:36}; 
FullP.F4 = FullP{:,37:42}; 
FullP.F7 = FullP{:,43:48}; 
FullP.F8 = FullP{:,49:54}; 
FullP.Fz = FullP{:,55:60}; 
FullP.Fp1 = FullP{:,61:66}; 
FullP.Fp2 = FullP{:,67:72}; 
FullP.P3 = FullP{:,73:78}; 
FullP.P4 = FullP{:,79:84}; 
FullP.Pz = FullP{:,85:90}; 
FullP.T7 = FullP{:,91:96}; 
FullP.T8 = FullP{:,97:102}; 
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FullP.P7 = FullP{:,103:108}; 
FullP.P8 = FullP{:,109:114}; 
% Delete old rows 
FullCorrelation(:,1:114) = []; 
FullP(:,1:114) = []; 
Write as Tables 
writetable(FullCorrelation,'Psych_Scores_And_EEG_Correlation.xlsx', 'sheet', 
'Correlations', 'WriteRowNames', true); 





 Load Variables 
 Subgroup Indexing by age used in functions below 
 List of EEG Locations 
 ANOVA 





Subgroup Indexing by age used in functions below 
TypAvgVi = find(Final_Cats == '0');                     % No ASD + Average or High 
Verbal IQ 
ASDAvgVi = find(Final_Cats == '1');                     % ASD DX + Average or High 
Verbal IQ 
ASDLowVi = find(Final_Cats == '2');                     % ASD DX + Low Verbal IQ 
 
TypAvgEEG = SampE2D(TypAvgVi, :); 
ASDAvgEEG = SampE2D(ASDAvgVi, :); 
ASDLowEEG = SampE2D(ASDLowVi, :); 
List of EEG Locations 
for i = 1:6 
    if i == 1 
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        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "High Gamma"; 
    elseif i == 2 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Gamma"; 
    elseif i == 3 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Beta"; 
    elseif i == 4 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Alpha"; 
    elseif i == 5 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Theta"; 
    elseif i == 6 
        zz(1,[i, i+6, i+6*2 i+6*3 i+6*4 i+6*5 i+6*6 i+6*7 i+6*8 i+6*9 i+6*10 ... 
        i+6*11 i+6*12 i+6*13 i+6*14 i+6*15 i+6*16 i+6*17 i+6*18]) = "Delta"; 
    end 
end 
for i = 1:114 
    if (i>=1) && (i<=6) 
        zz(1,i) = strcat('C3_', zz(1,i)); 
    elseif (i>=1+6) && (i<=6*2) 
        zz(1,i) = strcat('C4_', zz(1,i)); 
    elseif (i>=1+6*2) && (i<=6*3) 
        zz(1,i) = strcat('O1_', zz(1,i)); 
    elseif (i>=1+6*3) && (i<=6*4) 
        zz(1,i) = strcat('O2_', zz(1,i)); 
    elseif (i>=1+6*4) && (i<=6*5) 
        zz(1,i) = strcat('Cz_', zz(1,i)); 
    elseif (i>=1+6*5) && (i<=6*6) 
        zz(1,i) = strcat('F3_', zz(1,i)); 
    elseif (i>=1+6*6) && (i<=6*7) 
        zz(1,i) = strcat('F4_', zz(1,i)); 
    elseif (i>=1+6*7) && (i<=6*8) 
        zz(1,i) = strcat('F7_', zz(1,i)); 
    elseif (i>=1+6*8) && (i<=6*9) 
        zz(1,i) = strcat('F8_', zz(1,i)); 
    elseif (i>=1+6*9) && (i<=6*10) 
        zz(1,i) = strcat('Fz_', zz(1,i)); 
    elseif (i>=1+6*10) && (i<=6*11) 
        zz(1,i) = strcat('Fp1_', zz(1,i)); 
    elseif (i>=1+6*11) && (i<=6*12) 
        zz(1,i) = strcat('Fp2_', zz(1,i)); 
    elseif (i>=1+6*12) && (i<=6*13) 
        zz(1,i) = strcat('P3_', zz(1,i)); 
    elseif (i>=1+6*13) && (i<=6*14) 
        zz(1,i) = strcat('P4_', zz(1,i)); 
    elseif (i>=1+6*14) && (i<=6*15) 
        zz(1,i) = strcat('Pz_', zz(1,i)); 
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    elseif (i>=1+6*15) && (i<=6*16) 
        zz(1,i) = strcat('T7_', zz(1,i)); 
    elseif (i>=1+6*16) && (i<=6*17) 
        zz(1,i) = strcat('T8_', zz(1,i)); 
    elseif (i>=1+6*17) && (i<=6*18) 
        zz(1,i) = strcat('P7_', zz(1,i)); 
    elseif (i>=1+6*18) && (i<=6*19) 
        zz(1,i) = strcat('P8_', zz(1,i)); 
    end 
end 
ANOVA 
bb = NaN(10,1); 
cc = NaN(19,1); 
anovaTable = ["EEG_Location", "ANOVA_p-value", "MeanDiff/p-value", "Typ_ASDAvg", 
"Typ_ASDLow", "ASDAvg_ASDLow"]'; 
for i = 1:114 
    a = TypAvgEEG(:, i); 
    b = vertcat(ASDAvgEEG(:, i), bb); 
    c = vertcat(ASDLowEEG(:,i), cc); 
    d = [a,b,c]; 
    [p,~,stats] = anova1(d, [], 'off'); 
    if p <= 0.05 
        [p,~,stats] = anova1(d); 
        [e,~,h,gnames] = multcompare(stats); 
        figure(h) 
        yticklabels({'ASD Low Verbal', 'ASD Avg Verbal', 'Typically Developing'}); 
        f = [gnames(e(:,1)), gnames(e(:,2)), num2cell(e(:,3:6))]; 
        g = vertcat(zz(1,i),p, "MeanDiff", f(:,3)); 
        h = vertcat(NaN, NaN, "p-value", f(:,6)); 
        anovaTable = [anovaTable, g, h]; 
    end 
end 
Write Table 
t = array2table(anovaTable); 
writetable(t, 'Anova_Results.xlsx'); 
End 
 

